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ABSTRACT 
The positive impact of vaccines on global human health is second only to clean drinking 
water, sanitation and hygiene. The emphasis on safety in modern vaccines has motivated 
use of highly purified antigens to create subunit vaccines. However, these need to be 
formulated with adjuvants to be effective. Most vaccines require cold chain distribution 
and are administered via injection by trained healthcare personnel. This is logistically and 
economically challenging causing many people to be insufficiently vaccinated. 
Temperature stable oral subunit vaccines are ideal to overcome these challenges, but 
subunit vaccines require sophisticated oral delivery systems to survive the harsh conditions 
of the gastrointestinal tract. Vaccines in powder form are most suitable for use with such 
delivery systems and are often more stable than liquid forms. 
In this PhD project, a subunit vaccine formulation was designed using the protein 
ovalbumin as model antigen and an adjuvant system composed of cubosomes with Quil-A. 
Spray drying was used to produce a powder that formed the particulate vaccine formulation 
upon hydration. The vaccine was evaluated in vitro and showed good properties for 
vaccination. In addition, the antigen was stable in the powder during dry storage at 25oC 
for at least 6 months. A design of experiments approach was used to investigate the effects 
of four important spray drying parameters on key product characteristics. Input-output 
correlations were established and it was concluded that the method is robust with little 
impact of the parameters on vaccine-related characteristics thus allowing optimisation to 
focus on process or powder characteristics. The vaccine was highly immunogenic in vivo 
in mice when administered by s.c. injection, but ineffective following oral administration. 
The main goal of this PhD project was to evaluate microcontainers as oral vaccine delivery 
system. Microcontainers are small cylindrical polymer-reservoirs with an opening at one 
end. These were filled with the vaccine and then sealed with a pH-sensitive lid to carry the 
vaccine safely through the stomach and release it in the intestine. In vitro studies indicated 
that the microcontainers could protect the vaccine from the challenges of the 
gastrointestinal tract and deliver it safely to the small intestinal wall. However, they were 
unable to improve the oral immunogenicity of cubosomes with OVA and Quil-A in vivo. 
These results indicate that oral delivery systems such as microcontainers should be used to 
make vaccines with weak oral immunogenicity more potent rather than to deliver orally 
ineffective vaccines.  
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DANSK RESUME 
Vacciner har haft stor positiv indflydelse på den globale menneskelige sundhed kun 
overgået af rent drikkevand, kloakering og hygiejne. Den store fokus på sikkerhed i 
moderne vacciner har motiveret brug af oprensede antigener til at skabe subunit vacciner. 
Disse skal dog formuleres med adjuvanter for at være effektive. De fleste vacciner skal 
distribueres på køl og indgives ved indsprøjtning af trænet sundhedspersonale. Dette giver 
anledning til logistiske og økonomiske udfordringer som gør at mange mennesker forbliver 
utilstrækkeligt vaccineret. Orale vacciner der er stabile over for temperaturudsving er 
ideelle til at omgå disse udfordringer, men subunit vacciner kræver avancerede 
leveringssystemer for at kunne overleve de hårde betingelser i mavetarm kanalen. Vacciner 
på pulver form er velegnede til brug med sådanne systemer og er ofte mere stabile end 
vacciner på flydende form. 
I dette Ph.d. projekt blev en subunit vaccineformulering designet med proteinet ovalbumin 
som model antigen og et adjuvant system bestående af cubosomes med Quil-A. Spray 
tørring blev benyttet til at producere et pulver, der dannede den partikulære vaccine 
formulering ved hydrering. In vitro viste vaccinen gode egenskaber for vaccinering og 
antigenet var stabilt i pulveret i mindst 6 måneder ved tør opbevaring ved stuetemperatur. 
En design of experiments tilgang til forsøgsplanlægning blev benyttet til at undersøge 
effekten af fire spraytørringsparametre på vigtige produkt egenskaber. Input-output 
korrelationer blev etableret og det kunne generelt konkluderes, at metoden var robust, med 
lille indvirkning af parametrene på vaccine relaterede produkt egenskaber. Ved optimering 
kan der derfor fokuseres på proces- og pulver egenskaber. Vaccinen var effektiv in vivo i 
mus efter subkutan administrering, men havde ingen effekt oralt. 
Hovedformålet med denne Ph.d. var at evaluere mikrocontainere til oral vaccinelevering. 
Mikrocontainere er små cylindriske polymer beholdere med en åbning i den ene ende. Disse 
blev fyldt med vaccine og lukket med et pH-følsomt låg for at bringe vaccinen sikkert 
igennem maven og frigive den i tarmen. In vitro studier indikerede, at mikrocontainerne 
ville kunne beskytte vaccinen mod de barske forhold i mavetarm kanalen og levere den 
sikkert til tarmvæggen. Desværre forbedrede de ikke virkningen af cubosomes med OVA 
og Quil-A in vivo efter oral administrering. Resultaterne indikerer, at orale 
vaccineleveringssystemer bør benyttes til at forbedre virkningen af vacciner som har en vis 
effekt oralt, frem for at muliggøre oral levering af vacciner der er ineffektive oralt. 
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1. Introduction 
In the 18th century in Europe, smallpox affected all layers of society and was responsible 
for an estimated 10 % of all deaths. Many of those that survived were left with disfiguring 
scars and were often blinded [1–3]. While it had been known for millennia that survivors 
of a smallpox infection became immune to the disease, no cure had been found. The most 
successful means of fighting smallpox was the process of subcutaneously injecting a small 
amount of smallpox virus from pus isolated from infected individuals into non-immune 
people. This process was called inoculation (from inoculare – to graft) or variolation (from 
variola – smallpox) [2,3]. The philosophy was that the injection of a small amount of virus 
generally would not lead to detrimental disease but could protect against natural infection 
occurring from inhalation of uncontrolled amounts of virus [2]. Variolation had long been 
used in China and India by the time it was introduced in Europe in the 18th century [1]. 
While variolation was effective, it carried the risk of causing smallpox disease and 
transferring other infections to the recipient. Variolated subjects also sometimes conveyed 
natural smallpox infection to susceptible individuals in their surroundings [1,2]. Variolation 
was a risky procedure associated with a variolation induced fatality rate of 0.5-2 %, but it 
gave about 80 % protection against natural infection. Since the fatality rate of people 
naturally infected with smallpox was around 20-30 %, many chose variolation believing 
that the risk of dying from it was smaller than the risk of dying from natural infection with 
the virus [1,4]. 
By the end of the 18th century, based on observations of milk maids with a history of 
cowpox resisting variolation or smallpox infection, Edward Jenner hypothesised that 
cowpox infection could (i) protect against smallpox and (ii) be deliberately transferred 
between people in order to infer protection against smallpox [1,3]. In May 1796, Jenner 
injected an 8 year old boy, James Phipps, with matter from fresh cowpox lesions on a 
milkmaid. Phipps developed light disease, but recovered and was later challenged with 
injection of fresh matter from a smallpox lesion. Since Phipps was unaffected, Jenner 
concluded that Phipps was protected. Jenner named the process vaccination (from vaccinia 
– cowpox), distinguishing it from variolation [1–3]. Louis Pasteur later devised the 
principle of isolating, inactivating and injecting the disease causing organism to induce 
protective immunity on which subsequent vaccines were based for many years [5]. In 
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honour of Jenner, he generalized the use of the term “vaccination” to include the preventive 
inoculation of any infectious agent [1].  
Today, a number of vaccines are routinely administered in many countries, primarily to 
children and additional vaccines are often administered to people at risk, e.g. through travel 
to endemic regions [6,7]. Vaccines constitute the most significant medical contribution to 
public health and their positive impact on global human health is second only to clean 
drinking water, sanitation and hygiene [5,8,9]. The global eradication of smallpox after an 
extensive global vaccine effort organised by the World Health Organisation (WHO) [10] is 
a striking example of what can be achieved with effective global vaccination. However, the 
control of an infectious organism through vaccination relies not only on the availability of 
an effective vaccine, but also on a high vaccine coverage within a population.  
In 1974, the WHO initiated the Expanded Programme of Vaccination with the aim of 
ensuring that children worldwide have access to four routinely recommended vaccines: 
Bacillus Calmette-Guérin (protecting against tuberculosis), polio vaccine, measles 
containing vaccine (MCV) and the diphtheria-tetanus-pertussis (DTP) vaccine [11]. The 
program has been highly successful elevating the global coverage of the third dose of the 
DTP vaccine (DTP3 – often used as measure of vaccine coverage) from 5 % in 1974 to 83 
% in 2011 [12]. Since then, however, global coverage of the first dose of MCV (MCV1) 
and DTP3 has been stagnant leaving many children unprotected from infections that could 
be avoided through vaccination. [11,13]. In 2016, eight countries had DTP3 coverage rates 
lower than 50 %. Nearly all of them were facing conflict or serious economic turmoil thus 
greatly complicating the maintenance of vaccine coverage [11]. 
Most vaccines need to be kept at 2-8oC from manufacture to administration generating a 
logistic challenge referred to as the cold chain [14]. The vaccines are usually administered 
by injection by trained healthcare personnel [5]. In addition, most vaccines need to be given 
2-3 times with months between them to provide protection, and this can be infeasible in 
areas with limited access to healthcare [15,16]. The DTP vaccine is recommended to be 
given three times to all children. Nonetheless, 14 % of children worldwide did not receive 
the DTP3 vaccination leaving them unprotected, even though 34 % of them had received 
at least one DTP vaccination [11]. It is therefore imperative for global vaccine coverage to 
develop vaccines which can easily and inexpensively be distributed and administered in 
areas with limited logistical and healthcare infrastructure. 
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Heat stable self-administrable vaccines would be able to greatly reduce the problems of 
logistics, costs and repeated healthcare visits. They may therefore substantially improve 
vaccine coverage. The most attractive route of administration is the oral route, e.g. with the 
vaccine in a capsule [5,17]. Heat-stable vaccines in capsules can be distributed easily and, 
since needles are obviated, people can self-medicate according to an instructed vaccination 
schedule. Needles constitute the main risk associated with vaccination in developing 
countries through improper use. They additionally generate a large biohazardous waste 
problem that many developing countries lack the infrastructure to handle properly [13,17]. 
Oral vaccines hence solve many practical challenges associated with injected vaccines. 
Another important benefit of oral vaccines is the potential to stimulate both mucosal and 
systemic immunity providing better protection than parenteral vaccines, which mainly 
induce systemic immunity [18,19]. Oral vaccines can elicit mucosal immunity in the 
gastrointestinal tract (GI-tract) and at distant mucosal surfaces [20–22], e.g. the rectal or 
vaginal mucosa [23].  
Vaccines have traditionally been based on live attenuated or whole inactivated organisms 
which have a strong intrinsic immunostimulatory effect. However, these can have the risk 
of unacceptable side effects [5,24]. Modern vaccines are therefore based on highly purified 
antigenic fragments of pathogens, often peptides, instead of a weakened or killed form of 
the entire pathogen. These vaccines are referred to as subunit vaccines and have excellent 
safety profiles but are less immunogenic than whole organism vaccines. In order for them 
to be effective, they must therefore be co-administered with adjuvants – substances that 
improve the immunogenicity of the subunit antigen [5,17].  
Subunit vaccines are particularly challenging to develop for oral delivery for reasons 
described in sections 2.2 “Biological barriers of the gastrointestinal tract” and 3.2 “Oral 
vaccines”. Some of the issues may be overcome with the use of advanced drug delivery 
systems as e.g. microcontainers, which have lately been proposed as a promising system to 
improve oral drug delivery of small drug compounds that are poorly soluble in water and/or 
have poor permeability across the intestinal epithelium [25–27]. Microcontainers are 
polymeric devices in the micro-meter size range (Chapter 5). Those used by Nielsen et al. 
[27] and Mazzoni et al. [25] as well as for this thesis are cylindrical reservoirs with height 
and diameter of approximately 300 µm and an opening at one end allowing drug loading 
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and drug release. These are thought to have the potential to allow oral delivery of subunit 
vaccines [28], but have never been thoroughly evaluated for this purpose. 
 
1.1. Aim of this PhD project 
The aim of this PhD project was to apply microcontainers as an oral delivery system for a 
subunit vaccine formulation. To achieve this, the microcontainers should ideally (i) contain 
a high load of vaccine formulation, (ii) be sealed with lids that protect the vaccine from 
chemical and enzymatic degradation in the stomach and (iii) deliver the vaccine to the 
microfold cells (M cells) in the intestine.  
This implies a number of restrictions to the choice of vaccine. The ideal vaccine for use 
with microcontainers should (i) carry a high antigen load, (ii) be in a powder form that is 
stable at room temperature, (iii) be compatible with low-cost and high-throughput 
production and (iv) be effective at mucosal surfaces. Such vaccine properties can 
potentially be achieved using a spray dried subunit vaccine employing the inexpensive and 
mucosally active adjuvant Quil-A. The state of the art microcontainers developed in the 
Nanoprobes group at DTU Nanotech used together with a pH-sensitive polymer lid are 
potentially suitable to achieve the desired properties of the microcontainers. Therefore, this 
PhD project aimed to spray dry a vaccine formulation with Quil-A as adjuvant and 
ovalbumin as model antigen, load this into microcontainers and coat the loaded 
microcontainers with a pH-sensitive lid to deliver the vaccine safely through the stomach 
to the small intestine. 
To achieve the goal of this PhD project, two major accomplishments needed to be achieved. 
First, a subunit vaccine platform was chosen, designed, produced and characterised in vitro 
and in vivo. Second, microcontainers needed to be tailored for oral vaccination of mice. 
This included enlarging the cavity of the microcontainers, establishing a method to load the 
powder vaccine into the microcontainers and designing a lid for targeted release in the small 
intestine of the mouse. Finally, the system was evaluated in vivo.  
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1.2. Structure of the thesis 
This introductory chapter is followed by four chapters providing background for the PhD 
project. Chapter 2 gives an introduction to the immunology relevant for the PhD project. 
This is followed by a description of the biological barriers that need to be considered when 
designing an oral delivery system for vaccines and finally mucosal immunology. Chapter 
3 gives a general introduction to vaccines and oral delivery of these. The use of subunit 
vaccines is motivated and important elements to make them effective, namely 
immunopotentiators and particle delivery systems, are introduced. Immunopotentiators 
used in this PhD project are presented and those considered to be the gold standard briefly 
introduced. Important design characteristics for particle-based delivery systems for subunit 
vaccines are then discussed followed by a presentation of selected state of the art particle 
systems. In Chapter 4, the formation, structure and characteristics of cubosomes is 
presented. This is followed by a description of typical lipids used to make non-lamellar 
liquid crystals, important characterisation methods and a description of different strategies 
to produce cubosomes. Finally, spray drying of cubosomes and its motivation is presented. 
Chapter 5 introduces the microcontainers used for oral delivery of the vaccines. The 
experimental work and results obtained during this PhD are presented and discussed in 
Chapters 6-8. Chapter 9 provides an elaborated general discussion of important results from 
Chapters 6-8 and additional unpublished data are included where relevant. Chapter 10 and 
11 completes the thesis with general conclusions and future perspectives. 
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2. Physiology and immunology 
Vaccine design was entirely empirical in the days of Jenner and Pasteur. Since then, the 
science of immunology has developed greatly. The improved understanding of physiology 
and immunology along with the tools provided by other scientific progresses has paved the 
way for rational vaccine design [1] and improved preclinical experimental approaches to 
evaluate vaccine candidates [2–5]. In section 2.1 and 2.3, the immunology relevant for this 
thesis is presented, and in section 2.2, the physiology of importance to oral vaccination is 
presented. 
 
2.1. Immunology  
The immune system is often divided into two categories: the innate and the adaptive 
immune system. The innate immune response is fast responding (within minutes) and acts 
as the first line of defence but is generally not antigen specific [6]. It is comprised of 
physical barriers (e.g. the epithelium and mucus), soluble substances (e.g. the complement 
system) and phagocytic and antigen presenting cells (APCs) that recognize and interact 
with pathogens [7]. Innate immune cells recognize pathogens and distinguish them from 
self-antigens and non-pathogenic organisms via pattern-recognition receptors (PRRs). 
PRRs bind to pathogen-associated molecular patterns (PAMPs) expressed uniquely by 
pathogens [6]. Toll-like receptors (TLRs) are the most extensively described family of 
PRRs and agonists of these receptors have been shown to be potent vaccine adjuvants [8]. 
The cells of the innate immune system respond to PRR stimuli by inducing inflammation 
and recruiting the adaptive immune system to eradicate the infection [6].  
Most pathogenic organisms are dealt with by the innate immune system. When the innate 
immune system is overwhelmed by a pathogen, an adaptive response is stimulated. The 
adaptive immune response is specific to a specific pathogen and is based on recognition of 
unique epitopes on an antigen from the pathogen rather than general PAMPs. The adaptive 
immune response to a specific pathogen is acquired during the first exposure to it (the 
primary immune response). It takes longer to develop than the innate response, but is much 
more potent. After resolution of the infection, memory cells remain in the body allowing a 
strong antigen-specific immune response to be elicited fast upon later exposure to the same 
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antigen. This provides immunity to pathogens carrying the antigen [6]. The adaptive 
immune response is divided into two categories based on the effector mechanism of the 
response: the humoral and the cellular immune responses. The humoral immune response 
is mediated by antibodies and the cellular immune response is facilitated by cytotoxic T 
cells. The response elicited depends on how the antigen is presented by the APC, which in 
turn is determined by whether the antigen is present in the cytosol or in the endosomal or 
extracellular compartment (Figure 1) [9].  
 
Figure 1. Antigen presentation and T cell activation by antigen presenting cells. a) Extracellular 
antigens are internalised by APCs, broken down into peptides and presented on the surface of the 
APC in the context of MHC-II molecules. CD4+ T cells, also known as T helper or TH cells, 
recognise the MHC-II/peptide complex through their T cell receptor (TCR) and CD4+ surface 
molecules. The activated CD4+ T cell can then provide help for other cells specific to the same 
antigen epitope, as exemplified in the illustration by activation of B cells to become antibody 
secreting plasma cells and memory cells. b) Intracellular antigens are broken down into peptides 
and loaded onto MHC-I. The MHC-I/peptide complex is transported to the surface of the APC 
where it can be recognised by CD8+ T cells through their TCR and CD8 surface molecules. 
Activated CD8+ T cells proliferate and mature into cytotoxic T cells capable of killing other cells 
that present the same antigen/MHC-I complex on their surface. Modified from [10] with permission 
from Springer, Nature Chemical Biology, Copyright 2013. 
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Extracellular pathogens are taken up through phagocytosis and broken down to short 
peptides (typically 13-22 amino acids in length) in lysosomes by low pH and enzymes in a 
process known as antigen processing. These peptides are subsequently complexed with 
Major Histocompatibility Complex (MHC) II (MHC-II) molecules and presented on the 
surface of APCs for recognition by CD4+ T cells (described below) in a process referred to 
as antigen presentation (Figure 1a) [9,11]. MHC-II is mostly expressed by specialized 
immune cells such as macrophages, dendritic cells (DCs) and B cells [12].  
Intracellular pathogens (e.g. intracellular virus) are broken down by the proteasome 
complex in the cytosol creating short peptide antigens (often 8-10 amino acids). These are 
complexed with MHC-I molecules and presented on the surface of the cell for recognition 
by cytotoxic CD8+ T cells (described below). All nucleated cells are capable of expressing 
MHC-I molecules with antigen on their surface and can thereby be recognized and lysed 
by cytotoxic CD8+ T cells if they have been infected (Figure 2). However, in order for this 
to happen, naïve CD8+ T cells must first be activated by DCs to mature effector cytotoxic 
CD8+ T cells [9,13], as illustrated in Figure 1b.  
 
Figure 2. All nucleated cells are capable of expressing MHC-I. When a cell is infected by a 
pathogenic organism, it presents antigens from the organism on its surface in the context of MHC-
I. This allows cytotoxic CD8+ T cells to identify and kill infected cells without attacking healthy 
cells. Granzymes and perforins are examples of cytotoxic effector molecules produced by cytotoxic 
CD8+ T cells. Modified from [14]. 
 
DCs are present in an immature state in all parts of the body and have been recognized to 
play a central role in stimulation and regulation of adaptive immunity. Immature DCs 
sample antigens through phagocytosis, micropinocytosis and receptor mediated 
endocytosis. DCs mature upon activation by stimulation of PRRs, migrate to draining 
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lymph nodes and upregulate surface expression of co-stimulatory molecules. They serve as 
potent APCs in the peripheral lymphoid organs (lymph nodes, spleen and mucosal 
lymphoid tissues) and are the only cells able to stimulate activation of naïve CD8+ T cells 
to become effector CD8+ cytotoxic T cells. Internalised antigens can be presented by DCs 
on MHC-I molecules in a process called cross-presentation. DCs regularly present the same 
antigen on both MHC-I and MHC-II molecules and most pathogens therefore initiate both 
a CD4+ and a CD8+ response [9,15,16].  
Lymphocytes of two types comprise the effector cells of the adaptive immune response: B 
cells and T cells. Naïve lymphocytes travel with the blood to circulate the peripheral 
lymphoid organs and return to the blood via the lymphatics to re-circulate. The peripheral 
lymphoid organs are the sites where adaptive immune responses are initiated through 
frequent meetings between lymphocytes and APCs. T cells interact only with processed 
antigen bound on MHC-I or MHC-II on the surface of APCs (Figure 1). Once the naïve T 
cell meets its specific antigen in the context of an MHC molecule and is activated by co-
stimulatory molecules, it proliferates and differentiates into effector T cells. If co-
stimulation is absent, the T cell will in contrast develop anergy leading to tolerance 
(illustrated for a CD4+ cell in Figure 3). Effector T cells are classed based on surface 
proteins into CD4+ and CD8+ T cells [16,17].  
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Figure 3. T cell activation requires presentation of antigen on MHC molecules (signal 1) and 
activation by co-stimulatory molecules (signal 2), as illustrated here for CD4+ T cell activation by 
an MHC-II/peptide complex. Without co-stimulation, T cells will develop anergy leading to 
tolerance. Reprinted from [18]. 
 
CD4+ effector T cells are also known as T helper cells and have a wide range of functions 
that help orchestrate, strengthen and regulate the immune response. CD4+ T cells can for 
example stimulate B cells to become antibody secreting plasma cells (Figure 2a), amplify 
DC activation of CD8+ T cells or boost the activity of macrophages. CD4+ T cells can 
differentiate into several subsets of functional classes depending on their activation. The 
main classes are TH1, TH2, TH17, TFH and Treg, each providing help and regulation for 
different functions of the immune system [16].  
CD8+ effector T cells are known as cytotoxic T lymphocytes (CTLs) and are important for 
protection against intracellular infections and cancers. Mature CTLs travel from the 
secondary lymphoid organs they were derived from to sites of infection. Here, they mediate 
pathogen clearance by killing infected cells and secreting chemokines and cytokines that 
recruit and activate other effector cells such as neutrophils and macrophages. Infected cells 
are distinguished from healthy cells by the CTL, through display on their surface of MHC-
I with the antigen specific to the CTLs T cell receptor (Figure 2). After resolution of the 
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infection, 90-95 % of the CTLs undergo apoptosis leaving 5-10 % behind as a long-lived 
population of memory cells [5,19]. Generation of a CTL response can occur through 
activation by DCs on their own or with help (licensing) from CD4+ T cells. CD8+ T cell 
priming by DCs without CD4+ T cell help is typically observed from infections associated 
with strong inflammation [5,20]. In the absence of overt inflammatory signals, CD4+ T cell 
help is usually required to enable DCs to stimulate a CTL response. CD4+ T cell help is 
additionally crucial for the generation of long-lasting effective CD8+ T cell memory 
irrespective of the presence of inflammation during priming. While CTL responses 
generated without CD4+ T cell help often are effective in clearing the infection, the 
resulting memory population tends to be defective in its ability to generate effective recall 
responses following secondary exposure to the pathogen (Figure 4) [5,20,21].  
 
Figure 4. CD4+ T cell help is required for the generation of long-lasting effective CD8+ T cell 
memory. The graphs depict the magnitude of the CTL response to cellular non-inflammatory 
antigen. The primary response is weak and independent of CD4+ T cell help. However, only with 
CD4+ T cell help are long-lived functional memory cells created and thus the strong secondary 
response depends on CD4+ help. Reprinted from [22] with permission from Springer, Nature 
Immunology Reviews, Copyright 2004. 
 
In contrast to T cells, B cells interact directly with the native soluble antigen through their 
transmembrane immunoglobulins (Ig) known as B cell receptors (BCRs). Secreted Ig of 
the same specificity as the BCR are known as antibodies and are important for protection 
against extracellular pathogens and toxins. Upon activation by antigen, B cells proliferate 
and differentiate into antibody secreting plasma cells and memory B cells. Plasma cells can 
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produce 5 classes of antibodies: IgA, IgD, IgE, IgG and IgM (briefly presented below), but 
each cell produces only antibody specific to a single antigen [23,24]. Each class has 
different effector functions and biological properties [24,25]. 
Naïve but mature B cells exclusively express IgM and IgD on their cell surface [24,25]. B 
cell activation by antigen usually requires help from already activated CD4+ T cells specific 
to the same antigen, but they can also be activated independently of CD4+ T cells. Some 
microbial constituents, for example, that contain multiple repeating antigenic epitopes can 
activate B cells in the absence of CD4+ help. After activation, B cells undergo 
immunoglobulin isotype switching to produce IgG, IgE or IgA, and affinity maturation in 
which their DNA is rearranged to produce antibodies with higher affinity to the antigen. 
The antibody isotype that is produced depends on the type of T cell response occurring in 
response to the pathogen [26,27]. IgM antibody is expressed early in the B cells 
development before extensive affinity maturation has occurred. It is therefore less specific 
than other isotypes allowing quick IgM antibody responses to a variety of antigens. IgM 
functions mainly by opsonising antigen and activating complement. IgD antibody is 
expressed in serum at very low levels and its function remains unclear. IgE is important for 
immune defence against parasitic infections but is also associated with hypersentivity and 
allergy. IgG is the predominant isotype in serum and extracellular fluid with the longest 
serum half-life. It functions by activating the complement system, opsonising or 
neutralising antigen, and establishes antibody dependent cytotoxicity by activating effector 
cells such as natural killer cells to destroy the antibody coated antigen. IgA is the principal 
class in mucosal secretions (section 2.3), but exists also in the blood [24,27].  
 
2.2. Biological barriers of the gastrointestinal tract 
The main purpose of the GI-tract is absorption of nutrients and water from ingested 
materials. The human GI-tract consists of the mouth, pharynx, esophagus, stomach, small 
intestine, large intestine and anus (Figure 5). The small intestine is mainly responsible for 
nutrient absorption and is functionally divided into the duodenum (where bile and 
pancreatic secretions are introduced), jejunum and ileum. The large intestine is divided into 
the caecum, colon, rectum and anal canal [28]. The human GI-tract has a large surface area 
to accommodate sufficient absorption of nutrients and water [29]. Reports of the total 
surface area of the GI-tract traditionally range from 260-400 m2, but 30-40 m2 has more 
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recently been suggested [30,31]. The surface area of the small intestine accounts for more 
than 90 % of the total area of the GI-tract [31]. The large surface area is heavily exposed to 
ingested infectious organisms [29] and it is therefore equipped with physical and biological 
barriers to protect against constant infection [32]. For the purpose of this thesis, we shall 
restrict the discussion to the segments of the GI-tract most relevant to oral delivery of 
vaccines: the stomach, the small intestine and, for the case of some vaccines, the colon. 
Common to the three segments is that they are lined by an epithelium and coated with 
mucus. The main cell type of the epithelium is the absorptive enterocytes followed by 
mucus secreting goblet cells [33]. The epithelial cells are connected by tight junctions 
making the paracellular space impermeable [34,35]. Their apical surface is covered by a 
carbohydrate coat created by integral plasma membrane glycoproteins and glycolipids. 
This coat is known as the glycocalyx [36]. Below the epithelial layer is a layer of connective 
tissue (lamina propria) and then a layer of smooth muscle cells (muscularis mucosae) [33].  
 
Figure 5. Anatomy of the human GI-tract. The GI-tract starts at the mouth and continues through 
the pharynx, esophagus, stomach, small intestine (duodenum, jejunum and ileum), the large 
intestine (caecum, colon, rectum and anal canal) and finally the anus. Reproduced from the 
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)[37]. 
 
The main function of the stomach is to store and release food slowly into the intestine. 
Secretion of hydrochloric acid acidifies the stomach to a pH range of 1.0-2.5 in humans 
[34], although it may increase to around pH 5 after ingestion of a meal [38]. The low pH 
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chemically degrades food components and inactivates many ingested organisms [34]. The 
epithelial cells also secrete the proteinase pepsin, which is active at low pH and hydrolyses 
proteins into smaller peptides [35]. The epithelium in the stomach is lined by a thick mucus 
layer (40-450 µm) into which bicarbonate is secreted to neutralise the pH locally and 
inactivate pepsin. This separates the harsh luminal milieu from the epithelium thus 
preventing self-digestion [34].  
In the small intestine, the pH ranges from 6.2 proximally to 7.4 distally [39]. Bile and 
pancreatic secretions are added to the food chyme at the proximal end of the duodenum. 
The bile and bicarbonate ions from the pancreatic secretions quickly bring the pH of the 
acidic chyme from the stomach up towards neutral pH. Bile salts emulsify fats and 
pancreatic enzymes break down proteins, lipids and carbohydrates for absorption. This 
forms a significant barrier for subunit antigens [28,34]. A continuously replaced mucus 
layer covers the epithelium of the small intestine and effectively traps and clears pathogens 
and foreign particulates [30,40]. 
The mucus of the GI-tract is generated mainly by negatively charged glycoproteins called 
mucins, which entangle and cross-link adhesively and reversibly to form a dynamic 
viscoelastic gel [30]. Mucins can be divided into two classes: secreted gel forming mucins 
present in the mucus and cell bound mucins present in the glycocalyx [30,41]. Mucus 
consists mainly of 95-99 % water and 5-1 % glycoproteins, but it also contains lipids, 
carbohydrates, salts and other substances [30,42]. The gel forms a mesh which can 
sterically block the entrance of particles larger than a certain size. It contains hydrophilic 
regions of heavily glycosylated mucins and regions of naked proteins. Lipids adsorbed to 
naked protein domains compose 20 % of the dry weight of the mucus and generate a 
hydrophobic adhesive barrier making it difficult for hydrophobic substances to cross the 
barrier [30].  
Mucus in the GI-tract is present in two layers: a firmly adherent layer in connection with 
the glycocalyx and an overlying loosely adherent layer [33]. However, there is 
disagreement about whether the small intestine has both layers of mucus or only a layer of 
loosely adherent mucus [33,41]. The mucus layers have varying thickness through the GI-
tract, as illustrated in Figure 6 from measurements in rats [43]. In mice, the mucus appears 
to be thinner and vary differently according to the segment of the GI-tract than the 
thicknesses indicated in rats in Figure 6: in the ileum of C57Bl/6 mice (the strain used 
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throughout this PhD), the mucus thickness is approximately 210 µm [44] and in the distal 
colon it is approximately 125-150 µm [44,45]. Below the mucus layer is the glycocalyx of 
the epithelial cells (Figure 7). In contrast to the mucus, the glycocalyx is anchored to the 
cell membrane by transmembrane mucins. The glycocalyx of the enterocytes is 
approximately 0.5-1.5 µm thick and provides a dense barrier with properties similar to the 
mucus [41]. 
 
Figure 6. Schematic of the thickness of the two layers of mucus in the GI-tract of the rat: the firmly 
adherent mucus closest to the epithelium and the loosely adherent epithelium closest to the lumen. 
The mucus layer is continuous and does not follow the contours of the villi in the intestine. The 
table shows the measured mean thickness (µm) and standard error of the two layers of mucus. 
Figure reprinted from [43]. 
 
19 
 
 
Figure 7. Schematic showing the relatively thin glycocalyx coating of enterocytes under the mucus 
layer in the distal rat colon. Figure adapted from [41] with permission from Springer Nature, 
copyright 2011. 
 
The colon has been reported to have a pH of 6.6±0.7 with increasing pH from the proximal 
to the distal end [46]. It has lower enzymatic activity than the small intestine [34] and is 
covered by a much thicker mucus layer [30]. The colon further contains a large commensal 
microbiota that benefit the host by supplying nutrients, digesting foods that the host cannot 
digest on its own and helps prevent colonization by harmful organisms [32].  
The digestive function of the GI-tract and the presence of the commensal microbiota give 
rise to additional biological barriers for oral vaccination. Oral vaccines face dilution over 
the large surface area of the GI-tract and by mucosal secretions thus requiring large doses 
[47]. Repeated ingestion of large antigen doses, however, may lead to the generation of 
tolerance rather than immunity [48]. Tolerance is defined as suppression of the immune 
response to specific antigens and is important for avoiding that beneficial microorganisms 
and food substances are attacked by the immune system [32]. Soluble proteins are generally 
only taken up in small amounts and tend to induce immune tolerance [49] thus necessitating 
that oral vaccines express appropriate danger signals to trigger an immune response [35].  
For evaluation of oral vaccine delivery systems in mice, it is important to consider the 
differences of the GI-tract between humans and mice. The GI-tract of mice is composed of 
organs that are anatomically similar to those of humans although prominent differences 
exist, as illustrated in Figure 8. The large difference in body size obviously leads to large 
size differences of the organs. Other differences might be related to different diets, feeding 
patterns and metabolic requirements [29,50]. The stomach of some mouse strains is divided 
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into a non-glandular forestomach and a glandular part. The small intestine in the mouse 
does not have the mucosal folds (plicae) of the human small intestine, but has villi taller 
than those of humans to increase its surface area [50,51]. The small intestine to large 
intestine length and surface area ratios in humans are 7 and 400 while they are only 2.5 and 
18 in mice [50]. The caecum in mice is relatively large and is an important site for 
fermentation of plant materials and vitamin production, which mice reabsorb through 
coprophagy. The human caecum is, in contrast, relatively small, has no fermentation and is 
without a clear function. The thickness of the mucus in the mouse colon is thinner than that 
of humans and 85 % of the large intestinal microbiota of mice are not present in humans 
[50].  
 
Figure 8. Anatomy of the GI-tract in mice and humans. The relative sizes and lengths of the different 
segments of the GI-tract are quite different between man and mouse. Humans have a relatively 
larger small intestine and mice a relatively larger caecum and colon. Reprinted from [50]. 
 
Immunological differences are also present. Paneth cells are present in the small intestine 
of both species where they secrete antimicrobial compounds into the lumen. In mice, these 
cells are also present in the caecum but absent in the colon whereas they are present in 
small amounts in the colon of humans [50]. Peyer’s Patches are important sites for the 
induction of immune responses as described in section 2.3. The amount, size, distribution 
and composition of these vary between species and sometimes strain [52]. 
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 Of obvious importance to the evaluation in mouse models of oral drug and vaccine delivery 
systems that employ a pH-controlled release mechanism, are the differences between man 
and mouse in transit times and pH-ranges through the GI-tract. The pH of the stomach and 
small intestine of mice has been reported to vary between different strains of mice [51]. 
The pH of the stomachs of the common laboratory mouse strain Balb/c has been reported 
to be 3.0±0.3 in the fed state and 4.0±0.2 in the fasted state [53] thus being higher than what 
is generally reported in humans and oppositely affected by fasting than the pH of the human 
stomach. The pH of the small intestine of Balb/c mice was reported to be lower than in 
humans with a pH just below 5 in the small intestine of fed mice [53]. In C57Bl/6 mice (the 
strain used for our studies), the pH was reported to be 6.7 in the ileum [54] and thus closer 
to that of humans.  
The transit time through segments of the GI-tract is highly variable. In humans, gastric 
emptying time is often reported to range from 5 min to 2 h [39]. Transit times through the 
small intestine are often 2-4 h [55] and through the large intestine typically 6-32 h [39]. In 
a study by Padmanabhan et al, mice were orally gavaged with a radioactive label and 
visualised at various time-points showing labelling of the stomach and small intestine 
within 70 min, and of the entire GI-tract within 6 h [56]. This indicated that the transit time 
through the mouse GI-tract is much shorter than in humans as would be expected due to its 
much shorter dimensions and the relatively constant feeding pattern of mice. In Paper III 
(Chapter 8), the transit kinetics of microcontainers through the mouse GI-tract was 
investigated and showed that microcontainers reach the caecum within 60 min of 
administration and that more than 60 % of the number of administered microcontainers 
passed the small intestine within 90 min. Oral delivery systems for use in mice thus need 
quick release times which might not be optimal for humans. A further consideration 
important for the safety of the mouse in connection with oral administration, is that mice 
are incapable of vomiting [57]. 
 
2.3. Mucosal immunity 
Most pathogens enter the human body through mucosal surfaces [32,58], and mucosal 
immunity is therefore an important element in our immune system to keep infectious 
organisms at bay. Here, the meaning of mucosal immunity shall be restricted to the 
protection inferred at mucosal surfaces by the adaptive immune system and focus will be 
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on the GI-tract. The mucosal immune system is divided functionally and anatomically into 
the organised mucosa-associated lymphoid tissues (MALTs) and the diffuse lamina 
propria region and glandular tissues. The MALT is responsible for initiating immune 
responses and the lamina propria and glandular tissues are effector sites for humoral and 
cellular immune responses. The constant migration of antigen-activated immune cells 
between inductive and effector sites provides the basis for the common mucosal immune 
system [32]. The common mucosal immune system forms a network that makes it possible 
for immunisation at one mucosal site to provide immunity at other mucosal sites, as 
illustrated in Figure 9 [58]. However, the MALT is divided into anatomically distinct 
compartments and functions essentially independently of the systemic immune system 
[59]. There is also functional compartmentalisation of the MALT in the way that specific 
sites of induction tend to stimulate strong immune reactions in some but not all of the 
effector sites [59]. Orally administered vaccines can stimulate effector responses locally as 
well as at a wide range of distant mucosal sites (Figure 9) [59]. Oral vaccination may 
thereby allow for immunisation at distant mucosal sites that are less practical for vaccine 
administration. 
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Figure 9. Illustration of the common mucosal immune system and its compartmentalisation. The 
red shading indicates expression of mucosal IgA immune responses after vaccination by the oral, 
nasal, rectal or vaginal route. The strength of the response is indicated by the strength of the colour 
shading. The strongest response is generally seen at the site of immunisation and adjacent mucosae. 
However, oral and nasal vaccination can give strong immune responses at distant mucosal sites. 
Reprinted from [59] with permission. 
 
The epithelial cells of the GI-tract express a polymeric Ig-receptor (pIgR), MHC-I and -II 
and a range of secretory molecules and adhesion molecules [58]. The lamina propria 
beneath the epithelium is a major effector site of mucosal immunity and is host to B cells, 
T cells, macrophages and other immune cells [60]. Along the length of the small intestine 
are macroscopic lymphoid tissues known as Peyer’s Patches (PPs) in which DCs, B cells 
and T cells reside [29], as illustrated in Figure 10.  
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Figure 10. Schematic of the anatomy of the gastrointestinal mucosal immune system. It consists of 
two major components, namely the effector sites and the inductive sites. The effector sites comprise 
the lamina propria and the epithelium; the inductor sites comprise the PP’s, lymphoid follicles and 
dispersed APCs. PP’s are macroscopic lymphoid tissues containing APCs, B cells and T cells and 
are covered by follicle associated epithelium (FAE) in which M cells reside. Reprinted from [35] 
with permission. 
 
Dendritic cells residing in the lamina propria of the GI-tract can extend their dendrites past 
the epithelium and into the lumen thus allowing them to sample passing antigens [61]. 
Another important mechanism of antigen sampling by APCs is mediated by special 
epithelial cells called Microfold cells (M cells). M cells are present in the follicle-associated 
epithelium (FAE) in the intestine (e.g. lining the PPs). They take up organisms and particles 
smaller than 10 µm from the lumen of the intestine and transport them across themselves 
to the underlying APCs (Figure 10 and Figure 11) [62,63]. A deep invagination on the 
basolateral membrane of the M cell forms an extracellular compartment in the M cell where 
macrophages, DCs, B cells and T cells reside (Figure 11). Uptake of particles from the 
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intestine is followed by quick transcytosis of the intact particle to the APCs behind the M 
cell resulting in antigen processing and presentation [60,64,65]. M cells appear to be the 
main route of entry into the host for several enteric pathogens such as polio, human 
immunodeficiency virus and salmonella typhi [64,66] and are thus appealing vaccine 
targets. Uptake by M cells generally does not result in degradation and so antigens and 
microorganisms are generally transcytosed intact/alive across M cells to the underlying 
lymphoid tissue [60,64].  
 
Figure 11. Schematic of an M cell in follicle associated epithelium. M cells are covered with a 
thinner mucus than normal enterocytes and have short irregular microvilli allowing close contact 
with antigens in the intestinal lumen. They sample antigens and transcytose them to APCs present 
in a pocket in the M cell on its basolateral side for presentation to B and T cells. Reprinted from 
[66] with permission from Elsevier. 
 
In contrast to the absorptive villus epithelium of the intestine, the FAE contains few or no 
mucus secreting goblet cells and there is little mucus secretion by the FAE [67]. Dense 
regular microvilli and a thick glycocalyx on the apical surface of enterocytes inhibits close 
contact with bacteria and viruses [66,68]. The apical surface of M cells, however, differs 
from that of enterocytes (Figure 11): M cells have short irregular microvilli, a thin 
glycocalyx (20-450 nm in the rabbit PP, compared to a fairly uniform 500 nm for 
enterocytes) and lack integral membrane hydrolytic enzymes [67,68]. This facilitates 
uptake of macromolecules, organisms and particles by M cells [66,67].  
M cell-mediated antigen uptake is associated with the development of a secretory IgA 
(sIgA) response. Polymeric IgA is transcytosed across the mucosal epithelium by 
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interaction with pIgR and secreted into the lumen by cleavage of pIgR forming sIgA [58]. 
sIgA is the dominant antibody of the mucosal immune system and provides a first line of 
defence in the intestine. B cells activated in PPs or the mesenteric lymph node migrate to 
the lamina propria and differentiate into IgA secreting plasma cells. IgA differs from IgG 
in that it functions in an external environment where the systemic mechanisms employed 
by IgG (such as the complement system and phagocytes) are not available. IgA therefore 
mostly functions as neutralising antibody providing immune exclusion of pathogens by 
binding to them in the lumen of the intestine and preventing epithelial adhesion and 
invasion [69,70]. This is highly significant, as it provides protection against the pathogen 
before it enters the body thus preventing infection. IgA thereby reduces the virulence of the 
pathogen and hence reduces the spread of infection. Mucosal vaccines may consequently 
be more effective at inducing herd immunity than parenteral vaccines even if their efficacy 
is lower [71]. IgA is well suited to function in the protease containing intestine due to its 
extraordinary stability [69]. As a consequence, intestinal sIgA in its native form is expelled 
with the faeces and is regularly measured (e.g. with ELISA) to evaluate the mucosal 
immune response to experimental vaccines [72–74].  
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3. Vaccination 
Vaccines function by mimicking exposure to a pathogen without eliciting the illness caused 
by natural infection with the pathogen. This primes an immune response to the pathogen 
generating immune memory against subsequent infection from organisms carrying the 
same antigens. Most vaccines employ a prime-boost strategy in which the vaccine is given 
at several different time-points referred to as the prime and following boosters. The prime 
generates a slow primary immune response in which memory cells are generated. The 
subsequent boosters activate these memory cells in fast and increasingly stronger secondary 
immune responses. If the vaccinated subject is later infected with the natural pathogen, this 
infection will correspond to reinfection with a pathogen that the immune system already 
knows is hostile and knows how to deal with effectively [1]. The pathogen will therefore 
quickly be met by a strong and specific immune response thus preventing a noticeable 
disease course from the infection. 
 
3.1. Vaccine types of the present and future 
Vaccines have traditionally been based on live attenuated or killed/inactivated organisms 
[2]. Live attenuated vaccines consist of either a weakened form of the pathogen or of a 
closely related but non-pathogenic organism carrying the same antigenic epitopes (e.g. 
Jenner’s cowpox vaccine against smallpox in Chapter 1). These vaccines are the most 
potent and are capable of eliciting both strong humoral and cellular immune responses 
[1,3]. They generally require fewer administrations than inactivated or subunit vaccines, 
often confer lifelong immunity and can be delivered by the same route as the natural 
pathogen. These advantages can largely be ascribed to the close resemblance with natural 
infections due to their ability to replicate in the host and the presence of microbial 
compounds such as PAMPs that activate the innate immune system. The ability to replicate 
is at the same time, however, also the main disadvantage of live vaccines. In 
immunocompromised individuals, live vaccines may cause persistent infection and 
otherwise non-pathogenic strains may induce a disease course. There is also the risk that 
the attenuated organism reverts to virulence through random mutation and horizontal gene 
transfer thus regaining the ability to cause disease and possibly spread. Other drawbacks 
include the risk of severe adverse side reactions (e.g. local inflammation and systemic 
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disease), the need to handle the vaccine in a manner to keep the organism alive, and the 
inability of many diagnostic tests to discern between vaccinated and infected individuals 
[1]. Many microorganisms are in addition difficult to grow in vitro thus making production 
of whole organism vaccines impractical [4]. 
Inactivated vaccines consist of the disease causing agent killed or inactivated through 
treatment with heat or chemicals. This eliminates the ability of the vaccine to replicate thus 
improving safety but requiring several booster doses. Inactivated vaccines are additionally 
often cheaper to make and less sensitive to challenges (e.g. temperature fluctuations) during 
handling and storage. However, they are less potent than attenuated vaccines, often induce 
only weak cellular immune responses and are still associated with adverse side effects [1,2]. 
Advances in biotechnology have allowed more sophisticated approaches to vaccination to 
solve the issues associated with whole organism vaccines [5]. These include the use of 
DNA vaccines and subunit vaccines [6]. DNA vaccines consist of antigen encoding DNA 
inserted into a vector. Naked DNA in plasmid form can be coupled to nanoparticles, but a 
more promising method is to use recombinant vectors in which the ability of certain viruses 
to deliver DNA to human cells is exploited. The inserted DNA then leads to antigen 
production and secretion by cells in the host which can induce a strong immune response 
[7,8]. The existence of gene encoding DNA, however, is inherently connected to the safety 
concern of reversion to the disease causing virulent state [9]. An example of viral vectors 
is adenoviruses, which have been studied extensively for vaccines as reviewed elsewhere 
[10,11]. Adenovirus vectors were initially developed for gene therapy to replace missing 
or faulty genes, but this was abandoned due to their high immunogenicity leading to great 
interest in them as vaccine platform [12]. However, pre-existing or de novo immunity to 
the vector caused by natural infection prior to vaccination results in neutralising antibodies 
that reduce the uptake of the vaccine by APCs [10,12,13]. In an adenovirus based HIV-1 
clinical trial, safety concerns lead to the termination of the study before completion of 
enrolment. The concern was due to elevated HIV-1 infection rates amongst vaccine 
recipients with pre-existing neutralising antibodies towards the adenovirus vector [14]. 
However, this observation was later challenged by observations from other clinical trials 
[15]. The issue of neutralising antibodies to the vector may be circumvented by using 
vectors that do not naturally infect humans [16], hiding the vectors from neutralising 
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antibodies through surface modification [17] and using a heterologous prime-boost 
approach with different vectors for prime and boosters [10]. 
Subunit vaccines contain one or more highly purified antigens often in the form of proteins 
or peptides [5]. Protein and peptide antigens present a promising direction for vaccine 
design as they are recognised as offering the best safety profile [18]. There is no risk of 
reversion to a virulent form and the toxicity associated with whole cell vaccines and 
inactivated toxins is removed. Subunit vaccines also offer advantages in terms of 
production and licensing since consistent production of well-defined protein/peptide 
antigens can be done relatively easily and inexpensively [19]. Furthermore, subunit protein 
antigens from different pathogens can be combined in fusion proteins to create a vaccine 
against more than one infection [20]. The main disadvantage of subunit vaccines is a low 
immunogenicity. The high purity of the antigenic fragments means that microbial danger 
signals are not present and thus, the antigen is often not recognized as hostile by the immune 
system. This often results in the antigen being ignored by the immune system and may 
result in tolerance [19,21]. In order to achieve effective immunisation with subunit 
vaccines, the antigen must therefore be delivered with adjuvants (section 3.3). Appropriate 
choice of adjuvant allows stimulation of immune responses pertinent to the pathogen 
against which the vaccine is designed. Adjuvanted subunit vaccines can stimulate strong 
cellular immune responses in addition to humoral immune responses and are thus 
promising for vaccination against targets that have proven difficult to vaccinate against 
with inactivated vaccines [19]. 
 
3.2. Oral vaccines 
Oral vaccines against four enteric pathogens are routinely administered to humans. 
Examples of licensed vaccines are summarised in Table 1. Another oral vaccine against 
adenovirus Type 4 and Type 7, an upper respiratory tract disease, is currently approved by 
the Food and Drug Administration of the United States of America to military personnel. 
Oral delivery of the virus results in asymptomatic infection of the GI-tract leading to 
immunity in the upper respiratory tract. All of the oral vaccines exist as live attenuated 
vaccines based on the enteric pathogen that naturally has adapted to evade and cross the 
biological barriers of the GI-tract (section 2.2). The cholera vaccine, however, exists also 
in the form of inactivated vaccines, e.g. in the form of a recombinant cholera toxin B 
 38 
 
subunit and whole cell inactivated vibrio cholera O1 vaccine proving that oral vaccination 
is possible with non-live vaccines [11,22]. 
Table 1. Licensed oral vaccines compiled from [11,22] (non-exhaustive list). 
Trade name Infection Vaccine 
Sabin Poliomyelitis Live trivalent attenuated polio vaccine, Sabin 
strains 1,2,3 
Dukoral  Cholera Cholera toxin B subunit and inactivated whole cell 
Vibrio cholera 01 
Vaxchora Cholera Live attenuated cholera vaccine, CVD-10-HgR 
Vivotif Typhoid Live attenuated strain, Ty21a 
RotaRix Rotavirus Live monovalent attenuated human rotavirus, 
RIX4414 strain of G1P(8) type 
RotaTeq Rotavirus Live pentavalent attenuated rotavirus reassortants 
derived from human and bovine species 
None  Acute respiratory 
disease 
Live adenovirus Type 4 and 7  
 
Live viral vectors (section 3.1) have been widely investigated for oral vaccination and 
shown to be able to stimulate potent immune responses after oral administration [9,11]. 
However, subunit vaccines are desirable since they have better safety and their production 
is not hampered by difficulties in culturing microorganisms [9]. Nevertheless, oral 
administration of subunit vaccines is challenging. Protein antigens do not have the natural 
ability of enteric live attenuated vaccines to survive the chemical and enzymatic attack in 
the GI-tract and cross the biological barriers (section 2.2). The residence time in the small 
intestine is limited (3-4 h in humans [23] and much less in mice (Paper III, Chapter 8) 
demanding fast presentation of the antigen to APCs. Furthermore, not all adjuvants are 
active at mucosal surfaces. Oral subunit vaccines therefore need effective delivery systems. 
Several strategies to deliver protein antigens orally have been reported [9,11,22], some of 
which will be presented in section 3.3.2, but at present, none have been licensed for human 
use. 
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3.3. Adjuvants 
Adjuvants (from adjuvare – to help) are substances delivered together with an antigen to 
improve and modulate the immune response to the antigen [24]. The concept was first 
described by Ramon in 1925 and since then, a large group of structurally heterogeneous 
adjuvants have been developed [25]. Today, it is generally accepted that subunit vaccines 
need to be co-formulated with adjuvants to be able to generate effective immunisation 
against the antigen. The wide range of adjuvants stimulate immune responses in many 
different ways, however, they can be divided into immunopotentiating compounds (often 
referred to simply as adjuvants) and delivery systems. An immunopotentiating compound 
is a substance that stimulates and/or modulates the immune response to an antigen while 
delivery systems help to deliver the antigen effectively to APCs. In practice, delivery 
systems such as particles systems often have intrinsic immunostimulatory effects. 
However, the combination of antigen with a particle system and immunopotentiator(s) is a 
common strategy to achieve a strong immune response to the subunit antigen [24,25].  
 
3.3.1. Immunopotentiators 
A wide range of immunopotentiating compounds have been studied as reviewed in several 
places [9,26,27]. These include aluminium salts, bacterial components such as PAMPs, 
synthetic bacterial DNA, double stranded viral RNA, saponins, cytokines, a range of 
synthetic small molecules and other substances. However, only few have been used in 
licensed human vaccines [28].  
 
3.3.1.1. Aluminium salts 
Aluminium salts are the most widely used class of adjuvants and include aluminium 
phosphate, aluminium hydroxide and aluminium hydroxyphosphate [29,30]. The class was 
first discovered in 1926 [31] and introduced as adjuvant for inactivated diphtheria and 
tetanus toxoids in 1932. Since then, aluminium salts remained the only adjuvant in licensed 
human vaccines for approximately 70 years [28,32]. Aluminium salts have been used either 
by adding antigen to aluminium salt solution to form antigen-aluminium salt precipitate or 
by adding antigen solution to a preformed aluminium gel such that the antigen is adsorbed 
to the gel [33]. The latter has generally been preferred since it allows for much more 
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controlled and homogenous aluminium formulations because the antigen does not affect 
the structure of the adjuvant [33,34]. Both types of aluminium-based adjuvants are 
generally (although inaccurately as explained by Gupta [33]) referred to simply as alum 
[33] and this custom will be continued here. 
The mechanism of the adjuvant effect of alum is only recently beginning to be understood. 
Alum was long believed to function through a depot effect allowing the antigen to remain 
at the injection site for extended periods of time. This has since been disproven and a range 
of other mechanisms have been indicated. These include stimulation of the innate immune 
system through inflammation and enhanced antigen uptake by APCs through the particulate 
nature of alum. However, the molecular mechanisms are still debated [29,30,32].  
The key advantage of alum is that it has been used for almost a century and has a proven 
safety record [30,31]. Alum acts primarily by increasing antibody production and is 
therefore mostly effective against pathogens that can be eliminated by antibodies such as 
extracellular bacteria [28]. However, alum is often less potent than other adjuvants and 
cellular immune responses to alum-adjuvanted vaccines are almost absent. Alum-
adjuvanted vaccines have consequently not been effective against intracellular pathogens 
and other targets that cannot be eliminated through antibodies alone such as HIV, 
tuberculosis and malaria [28,34]. Other drawbacks include unpredictable adsorption of 
certain proteins and low stability of some adsorbates [35]. The immunogenicity of alum 
depends on the adsorption of antigen to alum [29,33]. This adsorption depends on physical 
and chemical characteristics of the antigen, the type of alum and conditions of adsorption 
(e.g. pH, temperature, size of gel particles and ionic strength of the mixture) and alum has 
therefore been described as difficult to manufacture consistently leading to batch-to-batch 
variations [33]. There are also some safety concerns related to the use of alum, such as the 
stimulation of IgE antibodies which may lead to IgE mediated allergic reactions [33]. 
Nonetheless, alum remains the gold standard for vaccination [35]. 
 
3.3.1.2. Bacterial toxins 
Alum is a poor inducer of mucosal immunity [27,36] and is not suitable for oral delivery 
[1]. Other adjuvants are therefore necessary for oral vaccines. The best studied mucosal 
adjuvants are the bacterial enterotoxins cholera toxin and Escherichia coli enterotoxin and 
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mutants and subunits of these [36]. These adjuvants increase the epithelium permeability 
and modulate the vaccine uptake by APCs and the response of lymphocytes. They have 
been used successfully for oral immunisation of mice, but are too toxic for use in humans 
[9,22]. 
 
3.3.1.3. Saponins 
The adjuvant activity of plant saponins has been known since 1951. In 1970, Dalsgaard 
showed a correlation between the source of the saponin and its activity. The most active 
saponins were those obtained by aqueous extraction from the cortex of the South American 
tree Quillaja saponaria Molina, also known as Soapbark tree or Panama wood [37,38]. 
Further purification to remove tannins and polyphenols results in a mixture of saponins 
known as Quil-A [38]. Quil-A consists of a mixture of triterpenoid- or steroidal glycosides 
[39]. Quil-A saponins are thus surfactant molecules with a hydrophilic (sugar) – lipophilic 
(aglycone) – hydrophilic (sugar) structure [38] and have been reported to form micelles in 
water at concentrations above 0.03 % [40]. 
The use of Quil-A in humans has been limited by reports of toxicity and by the difference 
in glycoside composition between different batches stimulating interest in purifying and 
characterising specific fractions [41,42]. Quil-A has been separated into 23 HPLC fractions 
comprising more than 60 individual compounds [42]. Some fractions of Quil-A retain the 
immunogenicity while showing improved safety over Quil-A [41,43]. One of the major 
fractions termed QS-21 is known for low toxicity and is the only fraction to have been 
evaluated in humans [44]. The chemical structure of QS-21 is shown in Figure 12. 
However, the use of QS-21 is associated with a number of limitations: difficulty in the 
purification process of QS-21 leads to yields lower than 0.0001 %, toxicity limits the dose 
to about 50 µg in human vaccines and QS-21 is unstable in aqueous solution at 
physiological pH at room temperature. These limitations for QS-21 has led to the 
development of safer and more stable synthetic variations suitable for large scale 
manufacturing [44]. However, Quil-A is heavily used in veterinary vaccines [45]. 
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Figure 12. Chemical structure of QS-21. QS-21 is a purified fraction of the adjuvant Quil-A, which 
comprises a range of related structures. Reprinted from [46] with permission. 
 
Quil-A has been studied in formulations with liposomes [47–51], immune stimulating 
complexes [52–57] and cubosomes [47,58]. It is a TLR-independent adjuvant capable of 
stimulating strong humoral and cellular immune responses (Paper I, Chapter 6). One of the 
particularly interesting characteristics of Quil-A, is its ability to stimulate a strong CD8+ 
CTL response, which is often difficult to obtain with non-replicating vaccines. CTL 
responses are crucial for protection against intracellular infections by killing infected or 
transformed (e.g. cancer) cells [38,59]. Saponins interact with cholesterol in lipid 
membranes giving Quil-A the ability to create pores in cell membranes [60,61]. This has 
been proposed to be an important mechanism for the immune activation of Quil-A as it may 
allow the vaccine to enter the cytosol of APCs (likely through endosomal escape). Quil-A 
thereby facilitates cross-presentation of the antigen and hence the stimulation of CTL 
responses. However, the mechanism of action of Quil-A is still not fully understood and 
other activities have been reported. These include inflammasome activation and co-
stimulation of T cells through binding to T cell receptors [62,63].  
Saponins are well tolerated when administered orally and crude forms of quillaja saponins 
are used as foaming agents in many food, beverage and cosmetic products [39,64]. 
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Saponins form a mucosally active adjuvant capable of stimulating humoral and cellular 
immune responses when administered orally [39,65,66]. The surfactant property of Quil-A 
means that it can act as a penetration enhancer. In a study on transcutaneous vaccines, 
Rattanapak et al. reported that cubosomes (described in section 3.3.3.3) increased the skin 
permeation of a peptide antigen and that the addition of Quil-A significantly further 
enhanced this effect [67]. The interpretation of this was that Quil-A increases skin 
penetration of peptides. It is possible that a similar effect may be seen at other non-invasive 
routes.  
 
3.3.1.4. Dextrans 
Dextran is a class of high molecular weight (MW) branched polymers composed of D-
glucose units. It is produced by a variety of bacteria and its physicochemical properties 
depend mainly on their MW and degree of branching which is determined by the bacterial 
source. Dextrans have been used in a range of drug delivery applications e.g. as oral tablet 
excipient, drug stabiliser and as controlled release polymer excipients.  
Dextran is mucoadhesive and can act as mucus permeation enhancer in mucosal protein 
delivery [9]. It has also been used as adjuvant in combination with other adjuvants, in a 
chemically modified form to improve its immunogenicity and in a cross-linked form 
creating microparticles [1]. Dextran microparticles have been associated with strong 
humoral immune responses when given together with alum and can substitute substantial 
amounts of alum thus reducing toxicity [68]. 
 
3.3.2. Particulate delivery systems 
The natural pathogens that the immune system has evolved to respond to are commonly of 
particulate nature. A wide range of particulates have been developed with sizes similar to 
those of natural pathogens as illustrated with classes of particles in Figure 13 [69]. Antigen 
delivery to APCs with particle formulations has been shown to be 1,000-10,000 times more 
efficient than delivery of soluble antigen [70]. As mentioned in section 3.3, the particle 
formulations are often also combined with immunopotentiators that can strongly increase 
the immunogenicity of the particulate vaccine and may be used to polarise the immune 
response towards a humoral or cell mediated response [71]. Furthermore, it is known that 
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soluble antigens generally are inefficiently cross-presented, whereas particulate forms of 
antigens of similar or larger size than viruses are more readily cross-presented [69]. It is 
therefore not surprising that antigens incorporated in micro- and nanoparticle formulations 
inherently are more immunogenic than soluble antigens [21]. Several physical and 
chemical properties of particles can affect their ability to deliver antigen to APCs and 
stimulate an immune response to the antigen [21,72]. These include the size, surface charge 
and incorporation of antigen as will be discussed below.  
 
Figure 13. Sizes of delivery systems and pathogenic organisms. A range of particle delivery systems 
have been developed with sizes similar to those of natural pathogens such as viruses and bacteria. 
Antigens delivered in nano- and microparticles are delivered much more efficiently to APCs than 
soluble antigens. Reprinted from [69] with permission. 
 
3.3.2.1. Particle size 
APCs have been reported to process particulate antigens ranging in size from 8 nm to 3 µm 
[21,69]. There is no clear indication of an optimal size within this range as reports often are 
in disagreement. These conflicting studies may be related to the different injection sites, 
methods of evaluation and particle compositions – the latter of which is often used to 
control the particle size [21,73]. Particles in the size range of 20-200 nm efficiently enter 
the lymphatic system in contrast to particles in the size range of 200-500 nm which must 
be carried into the lymphatic system by APCs [69]. However, newer studies have suggested 
that 1 µm large particles can also enter the lymphatics [74]. Smaller particles are reported 
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to be cleared faster from the injection site than larger particles and it has been suggested 
that after subcutaneous (s.c.) administration, small particle size may bias immune responses 
towards humoral responses and larger particles towards cellular immune responses [21,73]. 
However, following intra-muscular administration of a cationic liposome formulation, 
small and large liposomes (~200, 600, 1500 and >2000 nm) were seen to drain similarly 
fast from the site of injection, but larger particles were detected in higher levels in the 
draining lymph node. Based on cytokine and antibody measurements, the authors 
concluded that the type of immune response and the antibody production was unaffected 
by particle size, but that medium sized particles (~600 nm) were the most efficient at 
stimulating expression of pro-inflammatory cytokines [75]. 
For oral drug delivery, mucus can present a barrier that must be overcome to allow intestinal 
absorption of the drug. Particles can be engineered to avoid mucoadhesion and thus be able 
to diffuse through the mucus if they are sufficiently small to penetrate the mesh of the gel 
layer [76]. Particles as large as 500 nm have been reported to be able to diffuse through the 
mucus if made with suitable surface characteristics [77] as discussed in section 3.3.2.2. 
However, the biological barrier of mucus might be less pronounced for vaccines, since M 
cells are covered by a thinner mucus layer than the enterocytes outside the FAE [78] and 
since dendritic cells in the lamina propria are able reach into the intestinal lumen to sample 
antigens (section 2.3). M cells have been reported to transport particles of many types 
ranging in size from 20 nm to 10 µm. A lower size limit has not been established, but the 
upper limit is thought to be approximately 10 µm [79]. PP uptake of particles of size 1 µm 
has been observed to be equally as efficient as the uptake of 0.3 µm particles [80], but 
particles of 1-2 µm appear to be taken up more efficiently than larger particles [79,80]. 
 
3.3.2.2. Surface charge of particles 
The surface charge of particles is often evaluated by measuring the zeta potential of the 
particles [72,81]. The zeta potential is not necessarily equal to the surface charge, but it is 
often close and is readily measurable [82]. Zeta potentials have been correlated to the 
colloidal stability of particles [72,81] with increasing positive or negative charge resulting 
in increased colloidal stability through electric repulsion. Guidelines classify particles with 
zeta potentials of magnitude 0-10 mV and 10-20 mV to be highly unstable and relatively 
stable, respectively, whereas particles with zeta potentials of 20-30 mV and > 30 mV are 
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moderately or highly stable, respectively [83]. However, while colloidal stability depends 
on both electrostatic repulsive forces and van der Walls forces, zeta potentials only provide 
information about electrostatic repulsion [83]. Steric interactions from large molecules can 
also provide colloidal stabilisation and thus particles with zeta potentials much closer to 
zero than indicated in the guidelines above might have excellent colloidal stability [83,84].  
Particles with a positive surface charge are generally taken up more efficiently by APCs 
than negatively charged particles. This has been attributed to electrostatic interactions 
between the cationic particles and negatively charged cell membranes, and has been used 
to increase the immunogenicity of particles administered parenterally, nasally and to the 
pulmonary mucosa [21,72,73]. Cationic particles are additionally mucoadhesive due to 
electrostatic interactions with the negatively charged mucus (section 2.2) [85]. 
Mucoadhesion may increase the intestinal residence time of particles [78,86] and hence 
may prolong the exposure of the vaccine to the inductive lymphoid tissues of the intestine. 
It is also possible that mucoadhesion might reduce the dilution of the vaccine by 
gastrointestinal secretions [85]. However, it remains unclear whether a cationic particle 
surface charge is advantageous for oral vaccine delivery systems [87]. Mucoadhesive 
particles are likely to be trapped in the mucus and thus may not efficiently cross the mucus 
barrier [78,86,88]. Although PPs are covered by a thinner layer of mucus than the adjacent 
intestinal epithelium (section 2.3), they only account for ~1 % of the total surface area of 
the small intestine. It is therefore possible that the mucus barrier covering the normal 
absorptive epithelium might trap and clear particles targeted to the M cells before they 
reach the PPs [78]. Mucoadhesion could exacerbate this effect and thus other strategies 
might be preferable for oral vaccination. Hydrophilic and neutral or slightly negatively 
charged particles have been shown to be optimal for mucus penetration [89]. Such particles 
may further be produced to shed an outer coating and expose an inner cationic particle once 
they reach the epithelium for efficient uptake by APCs [88]. Other studies have found that 
highly negatively charged particles provide optimal particle uptake by PPs in vivo [80,90]. 
In summary, while cationic particles are generally accepted to increase the immunogenicity 
of parenterally administered vaccines, it is controversial how a cationic surface charge 
might affect the oral immunogenicity of vaccines. These controversies may in part be due 
to the effect of the composition of the particles used in the experiments. The hydrophobicity 
of the particle surface, for example, is thought to be an important factor for mucoadhesion 
[78,91]. Mucus is also known to cause agglomeration resulting in increased effective 
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particle size and increased trapping [91]. In addition, it is important to remember that zeta 
potentials are heavily dependent on the pH and also depend on the electrolytes and the 
particle concentration in the aqueous medium [83]. Perrie et al. measured zeta potentials of 
a cationic liposome formulation to be ~15 mV in simulated intestinal fluid (pH 7.4) and 
~40 mV in simulated gastric fluid (pH 2) [92]. The same group later measured the effect of 
varying pH on the size and zeta potential of anionic lipid vesicles as they have summarised 
in a figure [93] reprinted in Figure 14. Furthermore, nanoparticles are known to be coated 
with a protein corona in vivo which can change their size and zeta potential [94,95]. 
 
Figure 14. Effect of pH variation in the human GI-tract on the size and zeta potential of a liposome 
formulation. Both the size and the zeta potential are heavily affected by the pH of the buffer. 
 
3.3.2.3. Co-delivery of antigen and adjuvant 
It has been an area of controversy in the literature whether physical linkage of antigen and 
adjuvant is important for the immunogenicity of a vaccine. Kamath et al. reviewed a range 
of reports showing that physical linkage of antigen to immunopotentiator, either directly 
by conjugation or within a formulation, is required to stimulate strong immune responses 
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[96]. In contrast to this opinion, Coffman et al. stated in an earlier review that antigens do 
not need to be incorporated into a particle, but may be administered as soluble antigen 
together with antigen-free particles [71]. Indeed, White et al. reported that liposomes with 
mannosylated lipid core peptide (manLCP) constructs stimulated similar levels of antigen 
specific cytotoxicity when formulated in liposomes with Quil-A as when it was simply 
admixed with liposomes with Quil-A [49]. However, they also observed that when 
manLCP and Quil-A were formulated in separate liposomes, the immune response was 
reduced to a level comparable to manLCP liposomes without Quil-A. They therefore 
speculated whether soluble manLCP might adsorp to Quil-A containing liposomes. This 
would effectively create liposomes with both Quil-A and manLCP and thus support the 
notion that adjuvant and antigen need to be delivered in the same particle [49]. Kamath et 
al. similarly observed (using a different vaccine system) that administration of antigen and 
adjuvant in two separate syringes at the same site did not prevent the combined 
antigen/adjuvant activation of DCs [96]. Inspired by this, they investigated the kinetic 
determinants of adjuvanticity by varying the kinetics with which adjuvant and antigen were 
delivered to the draining lymph node. They concluded that the crucial element for 
stimulating a strong cellular immune response is to avoid exposure of lymph node resident 
DCs to antigen before activation by the adjuvant. Physical linkage was not necessary, but 
it was important that the adjuvant was delivered to the individual DCs at the same time as 
the antigen or earlier. The reason for this was suggested to be that antigen presentation 
without activation signals might result in tolerance rather than immune stimulation. 
Synchronous delivery of antigen and adjuvant was, however, not a requirement for 
antibody responses [96].  
 
3.3.3. State of the art particle systems 
A selection of common particle systems used in experimental vaccines is illustrated in 
Figure 15 [9,11,97–99].  
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Figure 15. Selection of particle formulation classes and related structures used for vaccine delivery 
in experimental systems [9,11,97–99]. 
 
3.3.3.1. Lipid-based particles 
A wide range of lipid particles have been developed including emulsions, liposomes, 
liposome-related structures and liquid crystals. A variety of emulsion-based adjuvants have 
been produced and some have been used in human and veterinary vaccines [98,100]. 
Liposomes and the related bilosomes and ISCOMs are discussed in the following, whereas 
lipid-based liquid crystals shall be discussed in section 3.3.3.3 and further in Chapter 4.  
Liposomes were first discovered in 1965 by Bangham et al. [101]. The use of liposomes as 
adjuvants for entrapped diphtheria toxoid antigen was reported by Allison and Gregoriadis 
in 1974 [102] and liposomes have since then been studied extensively as vaccine adjuvants 
[73]. Liposomes are spherical particles with one or more lipid bilayers surrounding an 
aqueous core (Figure 16). The lipid bilayer is often made from amphiphilic phospholipids 
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and cholesterol [19]. However, other lipids can also be used and it is possible to control the 
physicochemical properties of the liposome by varying the composition and manufacturing 
method [73]. The amphiphilic nature of the lipids facilitate self-assembly in water forming 
bilayers with the hydrophobic ends facing each other and the hydrophilic ends facing the 
aqueous environment [103]. This structure allows antigens and adjuvants with different 
properties to be incorporated into the same liposome. Hydrophobic substances are often 
incorporated directly into the lipid bilayer and hydrophilic substances may be encapsulated 
in the centre of the liposome or bound to the liposomal membrane [73]. Binding to the 
membrane can be through adsorption, electrostatic complexation with oppositely charged 
lipids or by conjugation to an amphiphilic anchor inserted into the lipid membrane (Figure 
16). The optimal loading strategy depends on the function of the compound and on the 
physicochemical properties of the liposome, antigen and adjuvant [73].  
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Figure 16. Schematic of the liposome structure and different loading strategies. Liposomes are 
composed of one or more lipid bilayers and an aqueous lumen. Several strategies exist for loading 
of hydrophilic and hydrophobic actives. a) lipophilic and amphiphilic actives can be incorporated 
into the lipid membrane, b) charged hydrophilic actives can be attached to an oppositely charged 
bilayer membrane by electrostatic interactions, c) hydrophilic actives can be encapsulated in the 
centre of the liposomes, d) nucleotides can be complexed with cationic lipids to become embedded 
between multiple lipid bilayers and e) hydrophilic actives can be covalently conjugated to lipid 
anchors incorporated into the lipid bilayer. Reprinted from [73]. 
 
Some adjuvants elicit unwanted side effects when administered freely. For example, the 
TLR-4 agonist monophosphoryl lipid A (MPLA) (the active moiety of a bacterial endotoxin 
lipopolysaccharide [104]) is pyrogenic [73] and saponins have haemolytic effects [43]. 
These side effects can be reduced by incorporation of the adjuvants into particles such as 
liposomes [41,73].  
Large development efforts have led to an array of vaccines with liposome based adjuvants 
being tested in clinical trials [73]. Two liposome-based adjuvants, virosomes and Adjuvant 
system 01 (AS01), have been used in vaccines licensed for human use or approved for pilot 
routine administration in selected countries where there is a high risk of infection, as 
reviewed elsewhere [105]. Virosomes (first licensed in a vaccine for human use in 1994) 
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are viral envelopes from influenza virus that have been emptied for inner core and genetic 
information, thus essentially becoming liposomes with viral envelope proteins on the 
surface. AS01 is a liposome adjuvant containing the immunopotentiators MPLA and QS-
21 [105].  
Liposomes are prone to membrane disruption by bile salts. Bilosomes are based on vesicles 
(niosomes) similar to liposomes formulated with bile salts in the lipid bilayer. The presence 
of bile salts in the lipid membrane protects it from emulsification by endogenous bile salts 
in the intestine. Bilosomes can thus protect encapsulated antigen from the harsh 
environment of the GI-tract and are able to stimulate humoral and cellular immune 
responses following oral administration [11,19].  
Immune stimulating complexes (ISCOMs) are another derivative of liposomes composed 
of phospholipids, cholesterol and saponins (often Quil-A) [11]. ISCOMs are self-assembled 
spherical hollow nanoparticles with a characteristic open cage-like structure similar to the 
stitching on a football and are often around 40 nm in diameter [11,106]. Quil-A is known 
to interact with cholesterol in lipid membranes (section 3.3.1.3) and this interaction is likely 
the reason for the unique structure of ISCOMs. Indeed, in the ternary phase diagram of 
phosphatidyl choline (phospholipid), cholesterol and Quil-A, ISCOMs form only when all 
three components are present [107]. The incorporation of Quil-A into ISCOMs reduces the 
toxicity of Quil-A while retaining its adjuvant effect [98].  
ISCOMs have been shown in several animal models to be potent adjuvants stimulating a 
balanced humoral and cellular immune response [11,39]. They have also shown promise as 
oral vaccine system in a range of studies, as reviewed by Sjölander and Cox [39]. However, 
while oral administration of some antigens in ISCOMs could stimulate immune responses, 
no effect was seen towards other antigens despite those vaccines being effective after 
parenteral administration. Another vaccine was ineffective after three oral administrations, 
but stimulated a serum IgG response and IgA secretion in the mesenteric lymph node and 
PPs following intraperitoneal priming and oral boosting. The reasons for the efficacy 
differences are unknown, but may be related to the antigens, differences in the ISCOM 
formulations, the doses of antigen and Quil-A as well as the employed immunisation 
schedules [39].  
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3.3.3.2. Non-lipid based particles 
Virus like particles (VLPs) are self-assembled nanoparticles in the size range of 20-200 nm 
composed of viral capsid proteins. They can resemble the authentic geometry of the virus 
they are sourced from, but do not contain any of its genetic material and are thus a safer 
alternative to attenuated virus [21,108]. VLPs have been shown to be potent adjuvants for 
stimulating CTL responses. Fusogenic properties allow them to disrupt or fuse with cell 
membranes and deliver their antigen cargo directly into the cytosol of APCs thus 
facilitating cross-presentation of the antigen [109]. The viral proteins comprising the shell 
of the particle forms repetitive arrays of conformational epitopes. These function as 
immunopotentiators through cross-linking of B cell receptors and thus stimulate potent 
antibody responses [24,69]. The particulate and repetitive structure further causes effective 
opsonisation and uptake of VLPs by APCs [108]. VLPs are consequently highly 
immunogenic without additional immunopotentiators, but can be even more potent together 
with immunopotentiators [69]. VLPs made from an orally transmissible virus have 
furthermore shown promising results for the use of VLPs for oral vaccination [110]. 
An important property of any vaccine that should not be overlooked is the simplicity and 
ease of manufacture [19]. Since VLPs spontaneously self-assemble from their protein 
components, the main manufacturing challenge is production and purification of those 
proteins. VLP proteins can be produced in expression hosts such as bacteria, insects, yeast 
and mammalian- or plant cells. Yeast cells in particular allow for rapid and efficient 
production of large quantities of VLP proteins and are used for production of commercial 
VLP based vaccines [108]. VLPs were the first nanoparticles used with a subunit antigen 
vaccine to be licensed in the United States of America in 1986. As of 2016, four VLP-based 
vaccines are licensed for human use and more were under preclinical and clinical 
development [21].  
Poly(lactic-co-glycolic) acid (PLGA) is a biodegradable and biocompatible synthetic 
polymer. PLGA has been studied extensively for a range of biomedical applications leading 
to great knowledge of the characteristics of the polymer formulation and therefore how to 
achieve desired particle properties such as degradation rate, release kinetics, size, and 
specific surface characteristics through coating with other polymers. Furthermore, the 
existing use of PLGA particles in parenteral drug formulations licensed for human use 
might expedite approval of new PLGA particle-based products [111]. The main advantages 
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of PLGA particles for vaccine purposes are their high loading capacity, their ability to 
protect encapsulated antigen from harsh in vivo conditions, and the possibility for sustained 
concurrent release of antigen and immunopotentiator [112].  
PLGA particles have shown promise for single-injection systems of both subunit vaccines 
(reviewed by McHugh et al. [113]) and the inactivated polio vaccine [114]. However, they 
may not be an optimal system for immunisation in prime-boost regimens. Kirby et al. 
reported that PLGA particles stimulated weaker immune responses than similarly 
adjuvanted liposomes after s.c. administration [115]. Furthermore, PLGA particles 
encapsulating antigens are associated with antigen stability issues due to exposure to 
organic solvents during formulation and acidification of the microenvironment inside the 
particles during polymer degradation [113]. Inclusion of basic excipients to neutralise this 
acidification has been reported to be crucial for the immune response to some vaccine 
antigens [116]. 
Oral vaccination using PLGA particles has been attempted with some success. PLGA 
particles with the immunopotentiator MPLA and ovalbumin (OVA) as antigen were able 
to stimulate a weak humoral immune response after oral administration similar to that of 
s.c. injected soluble OVA [111]. In a newer study, PLGA nanoparticles carrying an HIV 
antigen and three TLR ligand immunopotentiators were encapsulated in microparticles 
consisting of the pH-sensitive polymer Eudragit® FS30D (soluble at pH > 7) for large 
intestinal delivery. Oral administration of this vaccine formulation resulted in some 
protection against rectal viral challenge showing promise for the use of PLGA 
nanoparticles for oral vaccination when used together with enteric coatings [117].  
 
3.3.3.3. Liquid crystal nanoparticles 
Certain amphiphilic lipids can self-assemble to form liquid crystal structures in excess 
water. Lyotropic liquid crystalline phases include the lamellar, cubic and hexagonal phase 
[118]. A further discussion of these liquid crystal phases is provided in Chapter 4. Liquid 
crystalline phases can be macroscopic and, if prepared from amphiphiles with very low 
aqueous solubility, dispersed to form nanoparticles with the same internal structure as the 
bulk phase. Particles formed from the lamellar liquid crystalline phase are known as 
liposomes and were discussed in section 3.3.3.1. Particles based on the inverse hexagonal 
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phase are referred to as hexosomes and those of the inverse cubic phase as cubosomes 
[118]. Non-lamellar liquid crystalline structures such as cubosomes and hexosomes show 
fusogenic properties which have been suggested to contribute to delivery of antigens 
directly into the cytosol of APCs thus facilitating cross-presentation for stimulation of a 
CTL response [119].  
Cubosomes consist of a highly contorted lipid bilayer forming a continuous lipid domain, 
inside which is a network of two tortuous but non-intersecting water channels. Compared 
to liposomes, cubosomes have greater membrane resistance to rupture and their structure 
gives a much larger surface area relative to the particle volume [112]. The structure of 
cubosomes with hydrophilic and hydrophobic domains provides a similar ability to that of 
liposomes to incorporate compounds of different physicochemical properties. Cubosomes 
are as a result flexible in the types of antigens and adjuvant they can incorporate. However, 
since cubosomes have much more membrane than similarly sized liposomes, they may 
offer increased incorporation of active compounds over liposomes [120]. The use of 
cubosomes for vaccine purposes is relatively new. Rizwan et al. showed that cubosomes 
with MPLA and imiquimod as adjuvants, and OVA as antigen stimulated a strong immune 
response [120]. When compared to similarly adjuvanted liposomes and to OVA with alum, 
cubosomes stimulated equally strong humoral immune responses and significantly stronger 
cellular immune responses [120]. Cubosomes were also tested as single-injection vaccine 
by the same group using Quil-A as immunopotentiator [47]. Gordon et al. observed a lower 
antibody response of single injected cubosomes compared to OVA and alum given with a 
booster 14 days after the prime indicating that a booster is necessary when using cubosomes 
[47]. In a later study, cubosomes were used to potentiate the immune response to an 
inactivated virus with a polysaccharide immunopotentiator [97]. In all referenced studies, 
the cubosomes were made from the lipid phytantriol (presented in Chapter 4). 
Hexosomes are similar in structure to cubosomes, but their lipid membrane contorts into 
the inverse hexagonal structure instead of the inverse cubic (described in section 4.2.2). 
Like cubosomes, hexosomes provide a high loading capacity and flexibility with the actives 
they can incorporate [99], and have only recently been evaluated as vaccine carriers. The 
synthetic analogue of the mycobacterial lipid monomycoloyl glycerol (MMG) known as 
MMG-1, is known to be a strong stimulator of cellular immune responses. Rodrigues et al. 
designed hexosomes based on phytantriol with MMG-1 as immunopotentiator and the 
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chlamydia trachomatis serovar D major outer membrane protein as antigen [99]. The 
hexosomes were compared to a cationic liposome formulation of similar particle size and 
with the same adjuvant named Cationic Adjuvant Formulation 04 (CAF04) [99]. CAF04 
had been shown earlier by the same group to be a strong stimulator of humoral and cellular 
immune responses [121]. Hexosomes were found to stimulate significantly stronger 
humoral immune responses than CAF04, but much weaker cellular immune responses. The 
authors additionally varied the charge of hexosomes by adding charged lipids and found 
that charge was not responsible for the difference between hexosomes and liposomes. It 
was therefore suggested that other factors such as the particle structure might be responsible 
for the different biological performance of the two carriers [99].  
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4. Cubosomes 
Liquid crystalline phases, also called mesophases, share features of both solid crystals and 
melts. Many materials form a liquid crystal phase over a temperature range during the 
process of melting. These materials consequently melt over a temperature range in contrast 
to the abrupt transition generally expected for the solid-melt phase transition. The stability 
of such liquid crystals is controlled by temperature and they are referred to as thermotropic 
mesophases. Materials that form liquid crystals upon addition of solvent are called lyotropic 
mesophases. Lyotropic mesophases are formed by self-assembly of amphiphilic molecules 
by the addition of water and are characterized by having a thermodynamically stable 
morphology with long-range order in one, two or three dimensions [1,2]. Lyotropic liquid 
crystals generally exhibit no ordering on the atomic scale (melt) but have molecular 
ordering on a larger length-scale leading to a well-defined structure (crystal) [2]. 
The first report of dispersed particles of the bicontinuous cubic phase is from Patton and 
Carey in 1979 [3]. In their study on fat digestion, they discovered that particles of the 
bicontinuous phase formed when simulated gastric fluid was combined with bile salts and 
lipases [3]. A decade later, Larsson coined the term cubosomes to describe particles of the 
bicontinuous cubic phase. Larsson has following been credited with discovering that cubic 
phases can exist as bulk macroscopic phases and dispersed into particles with the same 
structure as the bulk phase [4].  
 
4.1. Self-assembly of particles from amphiphilic molecules 
The hydrophobic end of amphiphilic lipids is often referred to as the tail, and the 
hydrophilic end is referred to as the head. The principal driving force for self-assembly of 
amphiphilic lipids in polar solvent is the so-called hydrophobic effect. The hydrophobic 
effect refers to the minimisation of interactions between the non-polar hydrocarbon tails of 
the amphiphiles and the surrounding water [5]. It mainly stems from the strong hydrogen 
bonding between water molecules, which causes water to expel non-polar solutes that are 
incapable of forming hydrogen bonds [6]. The morphological structure of the amphiphile 
self-assembly aggregates is determined by factors such as the molecular shape and 
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concentration of the amphiphilic molecule as well as external factors such as temperature, 
pressure and pH [1,6]. 
The critical packing parameter (CPP), also known as the shape factor, is used to describe 
the molecular shape of amphiphiles. CPP is defined in Equation 1: 
 ܥܲܲ ൌ ݒܽ଴ ∙ ݈௖ (Eq. 1) 
where v is the hydrophobic tail volume, a0 the area of the head group/tail group interface 
and lc the length of the hydrophobic tail in the molten state [2,6], as illustrated in Figure 17.  
 
Figure 17. Illustration of the parameters v, a0 and lc determining the CPP used to describe the 
shape of amphiphiles. The CPP connects the shape of the amphiphile to the curvature of the 
lipid/water interface favoured by the system. v is the volume of the lipid tail, a0 the head group area 
and lc the length of the hydrophobic tail in the molten state. Reprinted with permission from [7]. 
Copyright (2016) American Chemical Society. 
 
The CPP connects the shape of the amphiphilic molecules to the curvature of the lipid/water 
interface favoured by the system. Oil-in-water systems with membrane curvature towards 
the chain region are referred to as Type 1 or normal phases, whereas water-in-oil systems 
with curvature towards the water region are referred to as Type 2 or inverse phases. A rule 
of thumb suggested by Kaasgaard and Drummond is that Type 1 phases occur where 
ܥܲܲ ൏ 0.5 and Type 2 where	ܥܲܲ ൐ 1. Planar phases giving rise to lamellar structure arise 
when 0.5 ൏ ܥܲܲ ൏ 1 [6], all as illustrated in Figure 18. Others suggest that Type 1 is likely 
to occur when ܥܲܲ ൏ 1 and Type 2 when ܥܲܲ ൐ 1 [2,8]. 
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Figure 18. The effect of the molecular shape of amphiphiles on their packing structure. Oil-in-water 
curvature results from CPP < 1, no curvature from CPP = 1 and water-in-oil curvature when CPP 
> 1. Figure adapted with permission from [8] © IOP Publishing. All rights reserved. 
 
It should be noted, that while this model is useful for explaining observed amphiphile phase 
behaviour, it is difficult to use predictively for novel systems since v, a0 and lc are difficult 
to estimate. The parameters are furthermore not constants, but depend on the local 
environment. Changes in temperature, pressure, pH, salt concentration and amphiphile 
concentration all affect the parameters [5,6]. 
 
4.2. Lyotropic liquid crystals 
Various systems of amphiphiles in solvent can express a wide range of lyotropic liquid 
crystal structures as reviewed elsewhere [2,6]. The lamellar, hexagonal and cubic phase 
will be presented here. 
 
4.2.1. Lamellar liquid crystals 
The lamellar mesophase (denoted Lα) has a simple one dimensional crystal lattice 
organising the amphiphiles into a planar sheet-like structure. The amphiphilic molecules 
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are arranged such that the heads are in contact with water and the tails face each other. This 
shields the tails from contact with water by forming a double layer structure. Lamellar 
sheets can be stacked on top of each other forming a layer of amphiphiles with head-head 
and tail-tail intersections [6], as illustrated in Figure 19. 
 
Figure 19. Illustration of the structure of stacked lamellar amphiphile bilayers. 
 
4.2.2. Hexagonal liquid crystals 
The hexagonal phase consists of densely packed cylindrical micellar columns arranged in 
a hexagonal two dimensional pattern. Bulk hexagonal mesophases exist in the normal, 
H1	ሺܥܲܲ ൌ 0.5ሻ, and inverse, H2 ሺܥܲܲ ൐ 1ሻ, configuration, as illustrated in Figure 20. In 
the H1 phase, a continuous water domain separates hydrophobic cylinders, whereas in the 
H2 phase, a continuous hydrophobic domain separates cylindrical water channels (section 
4.1). In both cases the hydrophobic tails are molten [2].  
 
Figure 20. Illustration of the structure of the normal hexagonal phase (H1) and the inverse 
hexagonal phase (H2). Adapted from [9] with permission from Elsevier. 
 
The H2 mesophase can exist as dispersed particles in excess water called hexosomes [10]. 
The inverse hexagonal mesophase is strongly affected by packing constraints because the 
distance from the centre to the unit cell boundary of the hexagonally packed rods is not 
constant thus creating a void which must be filled uniformly (illustrated in Figure 21). In 
single amphiphile systems, where all hydrophobic tails are of equal length, this causes 
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strong packing frustration as lipid tails are forced to tilt or stretch away from their preferred 
conformational states to fill the voids. Strategies that reduce this packing frustration 
therefore favour the formation of the H2 mesophase. The void volume is proportional to the 
water channel diameter and factors such as low water content and high CPP (e.g. through 
elevated temperature, hydrophobic chain unsaturation and decreased chain length) thus 
favour formation of the H2 phase [6,8].  
 
Figure 21. Illustration of packing frustration in the inverse hexagonal phase. The hexagonally 
packed cylindrical rods create a void indicated by the grey area. The area must be filled by additives 
or by energetically costly bending and stretching of the lipid chains. Reprinted from [6] with 
permission from the PCCP Owner Societies. 
 
4.2.3. Cubic liquid crystals 
The surface structure of cubic phases has a triply periodic saddle shaped geometry that can 
be modelled mathematically as infinite periodic minimal surfaces (IPMS) [2,6]. Minimal 
surfaces are surfaces in which the principal curvatures are equal in magnitude and opposite 
in sign giving a mean curvature of zero at all points. Principal curvatures are a mathematical 
concept describing the signed maximum and minimum curvature of the line obtained by 
the intersection between the surface and any plane containing the normal vector to the 
surface at the point in question (Figure 22) [11].  
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Figure 22. Principal curvatures of surface. The principal curvatures of the golden surface in a 
specific point are the signed curvatures of the red lines in the intersection between the surface and 
the planes of principal curvature. The planes of principal curvature contain the normal vector to 
the surface in the specific point and are rotated to obtain maximal signed curvature of their 
intersection with the surface. Figure reprinted from [12]. 
 
IPMS are infinite extensions of minimal surfaces giving a periodic structure. Three IPMS 
structures have been observed in amphiphile/water systems: the gyroid (G), diamond (D) 
and primitive (P) corresponding to the Ia3d, Pn3m and Lm3m space groups, respectively. 
These structures are illustrated in Figure 23 [6,8].  
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Figure 23. Structure of cubic phase minimal surfaces: A) diamond, B) gyroid and C) primitive. The 
top panels show the unit cell of the surface and the bottom panels show extensions of these forming 
cubic phase periodic minimal surfaces. Reprinted from [1] with permission from Elsevier. 
 
Cubic phases are bicontinuous mesophases meaning that they consist of two immiscible 
liquids that form continuous interpenetrating phases. These phases are formed by a single 
bilayer membrane similar to the lamellar membrane, but warped into the saddle shaped 
geometries described above [2]. As for the hexagonal mesophase, the cubic mesophase can 
exist as Type 1 (V1), with two interwoven cubic networks of hydrophobic channels 
surrounded by water (ܥܲܲ~2/3ሻ, or as Type 2 (V2), with two interwoven cubic networks 
of water channels surrounded by a hydrophobic phase of opposing hydrocarbon chains 
ሺܥܲܲ ൐ 1ሻ. The three cubic mesophases have also been described as a set of monolayers, 
giving rise to their names G, D and P. The G mesophase consists of a pair of 3-connected 
(gyroid) “Y” networks, the D of 4-connected “diamond” networks and the P of identical 
primitive 6-connected simple cubic networks [2].  
Inverse bicontinuous cubic phases have received growing interest for their potential as drug 
delivery system [13]. They have a porous structure [8] with highly tortuous water pores of 
a diameter typically close to 5 nm [14] and are thermodynamically stable, lasting 
indefinitely if the amphiphile is not degraded [15]. Hydrophobic and hydrophilic actives 
can be incorporated in the lipid and water phases of the V2 mesophase, respectively, 
allowing incorporation of a wide variety of actives. However, when substances are 
incorporated above a certain concentration, they can disrupt the cubic structure of the lipid 
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bilayer. This limits the amount of actives that can be loaded into cubosomes. Generally, 
lipophilic drugs will favour transformation to the H2 phase and hydrophilic drugs will 
favour transformation to the lamellar phase [14]. Furthermore, small changes in 
temperature can cause transitions between the different cubic phase structures and 
transitions to e.g. lamellar or hexagonal phases can result from larger temperature changes 
[2]. 
The V2 phase has been shown to be able to protect actives such as vitamins and proteins 
from external challenges (e.g. enzymatic or oxidative degradation). It additionally 
possesses the potential for sustained release as diffusion of water-soluble actives is delayed 
by the tortuosity of the water channels [14,15]. Bulk cubic phases are highly viscous and 
may be nearly solid [2] making them impractical to handle and unsuitable for injection [1]. 
Colloidal dispersion of the V2 phase, cubosomes, with the same internal substructure as the 
bulk “parent” phase can be obtained by various methods [1], as described in section 4.5. 
Cubosomes have been proposed to possess a similar capacity as the parent phase for 
sustained release of actives [15] and this has later been verified experimentally for the 
release of OVA by Rizwan et al. [16]. However, there are also studies showing that 
cubosomes do not offer sustained release [17]. Rizwan et al. discussed that the sustained 
release of OVA probably in part is related to OVA being a relatively large (45 kDa) and 
surface active molecule because small molecule drugs are known to be released quickly 
from cubosomes [16].  
 
4.3. Cubic phase forming lipids 
As evident from the discussion in section 4.1, certain combinations of hydrophilic head 
groups and hydrophobic tail groups are likely to provide a certain phase behaviour. A range 
of lipids have been identified to form non-lamellar liquid crystals. The most studied lipids 
are monoolein and phytantriol, whose chemical structures are shown in Figure 24 [5]. 
Monoolein has low solubility in water but can swell in aqueous medium [13]. It forms V2 
phase at low temperatures in excess water and transforms to H2 phase and inverse micellar 
phase at elevated temperature (Figure 25, section 4.5). Although, phytantriol has quite 
different chemical structure from monoolein and is an oil rather than a wax at room 
temperature, the phase behaviour of the two lipids is similar [18].  
 78 
 
 
Figure 24. Chemical structures of monoolein and phytantriol. Monoolein and phytantriol are 
commonly used lipid amphiphiles to form non-lamellar lyotropic mesophases. Adapted from [19] 
with permission from Elsevier. 
 
Monoolein is a naturally occurring lipid in the GI-tract being a product of the digestion of 
triglycerides. It is prepared commercially for use as a food emulsifier, although with limited 
purity. Monoolein has several desirable properties for vaccine purposes. It has been 
awarded with the “generally recognised as safe” status, is non-toxic, biocompatible and 
biodegradable [13,14]. Monoolein can be hydrolysed by acid and certain enzymes, and the 
presence of unsaturation further renders it susceptible to oxidative degradation [5]. 
Phytantriol is used commercially in the cosmetics industry and has the advantage that the 
purity of commercially sourced phytantriol is higher than that of commonly used 
monoolein sources (e.g. food additives sourced from Danisco such as Dimodan® MO 90/D 
used in this PhD). However, while it has greater purity, small amounts of impurities have 
been shown to strongly affect its phase behaviour [18]. Like monoolein, phytantriol is a 
biocompatible lipid regarded to be safe [20]. However, since phytantriol has neither ester 
bonds nor unsaturation, it is more resistant to chemical degradation than monoolein [5]. 
 
4.4. Structural characterisation of dispersed liquid crystals 
Dispersed liquid crystals have been characterised using a range of techniques as reviewed 
by Boyd et al. [18]. The most popular techniques are small angle x-ray scattering (SAXS) 
and cryogenic transmission electron microscopy (cryo-TEM) [18].  
The best way to determine the lattice structure of dispersed liquid crystals is through SAXS 
[2,5]. The crystalline lattice of liquid crystals diffracts x-rays in radially symmetric two 
dimensional patterns characteristic of the structural organisation of the lattice. These are 
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converted to one dimensional patterns in which the relative peak positions (Bragg peaks) 
allow determination of the crystal lattice structure of the sample. The position of the peaks 
additionally provide information about the size of the lattice [5,18]. The relative Bragg peak 
distances expected from selected liquid crystal structures are shown in Table 2. At least 4 
peaks in a spectrum should be obtained for confident statements about the symmetry aspect 
of the mesophase which is used to determine the structure [2].  
Table 2. Relative spacing between Bragg peaks in SAXS diffraction patterns from selected liquid 
crystal phases. Table compiled from Hyde [2] and Wörle et al. [21]. 
Mesophase Descriptor Peak ratios 
Lamellar Lα 1: 2: 3: 4: 5: 6… 
Hexagonal H1, H2 √1: √3: √4: √7: √9: √12… 
Bicontinuous cubic G (Ia3d) √6: √8: √14: √16: √18: √20… 
 D (Pn3m) √2: √3: √4: √6: √8: √9… 
 P (Lm3m) √2: √4: √6: √8: √10: √12… 
 
SAXS provides excellent information, but also has limitations. Amphiphiles used to make 
liquid crystals are typically organic molecules consisting of atoms with weak electron 
density leading to low scattering intensity. The signal intensity will be further lowered by 
the low particle concentrations commonly used in the dispersions and therefore 
conventional SAXS instruments require hours of acquisition. Synchrotron radiation sources 
can greatly increase x-ray flux thus reducing necessary acquisition times to seconds and 
allow characterisation of structural changes in response to stimuli [5,18]. Another 
limitation of SAXS is that it does not provide information on single particle structure. 
Therefore, in systems with a mixture of particle morphologies, SAXS may not lead to 
identification of all particle systems present [10]. 
Cryo-TEM allows direct visualisation of particles dispersed in aqueous medium. Regular 
electron microscopy techniques operate in vacuum and require the removal of solvent. 
However, since lyotropic mesophases only form in the presence of solvent (usually water), 
this would result in loss of the internal structure of the mesophase. It is therefore necessary 
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to vitrify the samples in order to retain the structure. Cryo-TEM relies on almost instant 
freezing of a thin film of water in which the particles of interest are dispersed. Equilibrium 
structures are thus trapped in the ice providing a “snap shot” of the particles in dispersion 
[5,18]. One of the main advantages of cryo-TEM is the ability to visualise single particles. 
This allows identification of co-existing particle types with different internal structures 
including those that may not be visible on SAXS measurements [10]. Cryo-TEM studies 
have revealed that cubosomes often co-exist with vesicles and commonly have vesicles 
attached to their surface. These have been speculated to stabilise the cubosomes or to be 
precursors in a kinetic cubosome forming process. A major disadvantage of cryo-TEM is 
the inability to study dynamic changes [18]. 
Cryogenic field emission scanning electron microscopy (cryo-FESEM) has recently been 
suggested for characterisation of dispersed liquid crystals [1]. Cryo-FESEM provides three 
dimensional information on particle structure in contrast to cryo-TEM.  
 
4.5. Production of cubosomes 
Cubic mesophase can exist in three forms: precursors that form cubosomes upon hydration, 
macroscopic bulk gel and particle dispersion (cubosomes) [22]. Cubosomes can be 
produced by the top-down strategy through dispersion of bulk inverse bicontinuous cubic 
phase gel or by the bottom-up strategy in which dispersed cubosomes are created directly 
or from precursors [5]. The top-down strategy is the most common method for producing 
cubosomes. In this method, amphiphiles are first hydrated to drive their self-assembly into 
an inverse cubic phase bulk gel in a fully swelled state. A large energy input is subsequently 
required to break up the gel into particles. This is often done through high-pressure 
homogenisation, ultrasonication or high speed shearing and it is usually necessary to add 
steric stabilisers to obtain a stable dispersion of submicron cubosomes [5]. The top-down 
preparation of monoolein- or phytantriol-based cubosomes typically results in particles of 
200-300 nm in diameter with a polydispersity index (PDI) of 0.1-0.4 which can be stable 
against aggregation for up to one year [5,16]. However, the prerequisite formation of bulk 
gel and the methods to disperse it may be difficult to scale up and the high-energy 
dispersion of bulk gel generates heat which might degrade sensitive components added to 
the bulk phase [5,16,23]. 
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The bottom-up approach of hydrotrope dilution was first introduced in 2001 by Spicer et 
al. to overcome the drawbacks of the top-down approach [24]. In this method, a cubosome 
precursor mixture of monoolein dissolved in ethanol was diluted with water containing the 
steric stabiliser pluronic 127 to generate cubosomes with minimal energy input [24]. The 
critical parameter to this method was the use of a hydrotrope. Hydrotropes are amphilic 
materials without surfactant properties and are thus incapable of surfactant phase behaviour 
such as micelle formation. They characteristically have short compact hydrophobic tails in 
contrast to the longer tails of surfactants [25] and prevent liquid crystal formation only at 
high hydrotrope concentrations [23]. The ternary phase diagram for the 
monoolein/water/ethanol system can be used to design a cubosome forming dilution 
process (Figure 25). A single phase isotropic liquid of low viscosity is present in the region 
of the ternary phase diagram where the ethanol concentration is above 10 %. This liquid 
forms cubosomes upon dilution with water into the areas between the cubic phase regions 
and the isotropic liquid region. An example of the process is illustrated with the “dilution 
path” in Figure 25 [24]. The hydrotrope dilution method was later shown to be applicable 
for a range of other amphiphile/water/hydrotrope systems as well [16]. 
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Figure 25. Ternary phase diagram of the water/ethanol/monoolein system at 25oC. The system 
exhibits four single phase regions including the cubic mesophases of structure Pn3m and Ia3d and 
the lamellar mesophase. These mesophases extend as high as 10 % ethanol. The large region of 
isotropic liquid provides flexibility for the formulation of precursors to form cubosomes or cubic 
gel upon dilution in water. An example of the generation of cubosomes by dilution with water is 
indicated with the dilution path line. Adapted with permission from [24]. Copyright (2001) 
American Chemical Society. 
 
The dilution-based approach avoids laborious fragmentation and is more efficient at 
generating small particles than the fragmentation approach. In addition, cubosomes 
prepared through dilution with appropriate stabilisers can show long term colloidal stability 
[26]. However, designing a dilution-based process is complicated as it relies on knowledge 
of the ternary phase diagram (amphiphile/water/hydrotrope) as well as the effect of 
additives such as stabilisers and biological actives. Furthermore, the addition of a 
hydrotrope complicates the cubosome preparation as the individual components often will 
have different solubilities in the hydrotrope. The use of a hydrotrope also has the potential 
drawback that the hydrotrope could give rise to adverse effects upon administration [5,26], 
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although this drawback may be alleviated by drying the precursor mixture as will be 
described in section 4.6. 
 
4.6. Spray drying cubosomes 
Most vaccines are sensitive to temperature fluctuations, heat and/or freezing. Live vaccines 
are generally more sensitive to potency loss at elevated temperatures, whereas inactivated 
and subunit vaccines often tolerate moderate heat exposure. These vaccines are, however, 
often sensitive to freezing. This is mostly due to adjuvants such as alum, which might 
collapse upon freezing thus lowering its adjuvant effect [27]. The cold chain was developed 
to accommodate both of these types of vaccines. Unfortunately, cold chain problems are 
common and have been documented in all countries where temperature monitoring has 
been conducted, including developed countries [27]. Formulation of vaccines in powder 
form can improve their stability and spray drying has been suggested to be an ideal drying 
method for some vaccines [28]. Ohtake et al. reported a substantial improvement in the 
stability of a commercial live attenuated measles vaccine when using spray drying 
compared to the commercial lyophilised product. The loss of activity during drying was 
also reduced compared to lyophilisation [29]. Powder forms of vaccines furthermore avoid 
the need to transport bulk water and gives access to a wider range of applications [22,29]. 
Cubosome precursor powders have been produced by freeze-drying [30] and spray drying 
[22,31–33]. Spray drying is a method consisting of three steps: atomisation of the liquid 
feed, evaporation of the solvent and collection of the powder [34]. The spray drying process 
employed during this PhD project is illustrated in Figure 26, but many variations are 
possible as reviewed elsewhere [35]. The high temperature of the drying air used for spray 
drying has been a cause of wonder regarding how heat-labile biologicals can resist heat 
induced denaturation during spray drying. The explanation is related to the constant 
evaporation and short transit time through the hot drying chamber. At the early stage of the 
drying process where the air is hot, the droplet surface remains saturated with moisture. 
Moisture constantly and rapidly evaporates from the droplet surface and the droplet is 
therefore maintained at the wet-bulb temperature, which is considerably lower than the 
temperature of the surrounding air. At the later part of the drying process, the droplet 
surface can no longer remain moisture saturated and the evaporation driven temperature 
difference between the droplet and the surrounding air decreases. However, at this time the 
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biological is primarily in the solid state where it is more tolerant to heat. The temperature 
of the surrounding air has at the same time been reduced due the evaporation that has 
already taken place [34]. The maximal temperature the dry biologicals might experience is 
the therefore the outlet temperature of the spray dryer [35] and thermal denaturation of 
biologicals is consequently rare [34].  
 
Figure 26. Schematic of the spray drying process used for this PhD project. A feed solution is 
pumped into a drying chamber and dispersed into a fine mist by an atomising air flow. A hot air 
flow dries the particles in the drying chamber and carries them into the cyclone. In the cyclone, 
particles are deposited by centrifugation and fall down to a collecting chamber below. Adapted 
from Paper I. 
 
Spray drying has received growing interest due to its relative simplicity, scalability and 
cost-effectiveness [28]. Engineering of the powder particles is possible as reviewed 
elsewhere [28] and sterile spray drying is also feasible [36]. In relation to this PhD, an 
important advantage of spray drying is that it can directly form a fine flowable powder [34] 
making it possible to fill it into microcontainers without further processing (Paper I). This 
is in contrast to freeze drying, which tends to form a cake or a cotton-like substance which 
would need to be broken into particles through a secondary process [34]. 
Motivated by the extended applicability of dry powder forms of cubosomes, Spicer et al. 
developed a spray drying method to produce cubosome precursors [22]. Solid monoolein 
can theoretically be fragmented into small particles, but the sticky waxy nature of the lipid 
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causes powder cohesion. Stabilisers must therefore be added to encapsulate the lipid and 
reduce powder cohesion [23]. Spicer et al. first spray dried a mixture of monoolein, water 
and hydrophobically modified starch. When using a low MW starch (84 kDa), a powder 
yield of 78 % w/w was obtained and the spray drying process was reported to result in a 
non-cohesive powder of cubosome precursors encapsulated in starch shells. The powder 
was easily reconstituted into colloidally stable cubosomes upon addition of water, with the 
hydrated starch now acting as steric stabiliser of the dispersed cubosomes. However, the 
monoolein/water/starch system was difficult to spray dry because cubosomes formed 
immediately upon hydration of monoolein and starch. This caused a need for high energy 
processing of the spray drying feed and frequent clogging of the spray drying nozzle 
[22,23]. The hydrotrope dilution method (presented in section 4.5) was therefore adapted 
for spray drying and ethanol was used as hydrotrope to dissolve the liquid crystals. As 
starch is insoluble in ethanol, it was replaced with dextran [22] which has finite solubility 
in mixtures of ethanol and water [37]. Mixing ethanolic monoolein with aqueous dextran 
resulted in a low viscosity emulsion that could easily be spray dried to form a stable 
flowable powder of fine particles. These were thought to consist of monoolein encapsulated 
in dextran shells. The powder could be easily hydrated to form a dispersion, but tended to 
agglomerate over time although it could easily be redispersed. The authors explained the 
better ability of starch to provide colloidal stabilisation to be related to its favourable 
balance of hydrophilicity and hydrophobicity helping it interact with both water and lipid. 
Dextran on the other hand is mainly hydrophilic and thus does not interact much with the 
lipid bilayers [22].  
The method of Spicer et al. [22] was later adapted by Nielsen et al. [31] to produce 
cubosomes carrying the protein OVA. Nielsen’s method was adapted in this PhD project 
to produce a dry powder vaccine formulation consisting of cubosomes with OVA as model 
antigen and Quil-A as adjuvant. OVA has been reported to resist ethanol induced 
aggregation at ethanol concentrations up to 20 % w/w in the ternary water/ethanol/OVA 
phase diagram at OVA concentrations below ~5 % w/w and a temperature of 20-40oC [38]. 
For this reason, an ethanol concentration of 20 % w/w in water disregarding the presence 
of monoolein, dextran, OVA and Quil-A was used in this thesis. This should not cause 
aggregation of the OVA since the OVA concentration in the mixture used here is several 
orders of magnitude below 1 %. At the same time, it is a sufficient concentration to ensure 
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that ethanol will exert its hydrotropic effect on monoolein providing a low viscosity liquid 
for the spray drying feed [22].  
A limited number of microcontainers can be loaded into a mouse sized capsule. This was 
an important formulation constraint, since it limits the dose of cubosome precursor powder 
that can be administered orally to mice in microcontainers. For oral vaccination, antigen 
doses are generally required to be 10-100 times higher than the necessary dose for injected 
vaccine [39]. The OVA concentration in the spray drying feed was therefore increased to 
obtain a high load of antigen in the powder, and thus facilitate later use of the formulation 
in microcontainers carrying an appropriate antigen dose in a mouse capsule. The spray 
drying process and the in vitro and in vivo evaluation of the produced cubosome precursors 
as vaccine system is presented in Chapter 6 (Paper I). 
Typical effects of varying different spray drying parameters on characteristics of the spray 
dried powder are summarised in Table 3, which can be used as a rough guide when 
developing a spray drying process. However, due to heterogeneity in the behaviour of 
various substances during drying, optimisation is usually done in a trial-and-error manner 
[35,40]. The outlet temperature cannot be controlled directly, but depends on the other 
parameters (Table 3) [35,40].  
Table 3. General effects of spray drying parameters on process parameters (outlet temperature and 
yield) and powder product parameters (particle size and humidity). ↑, ↑↑ and ↑↑↑ indicates mild to 
strong increase and ↓, ↓↓ and ↓↓↓ mild to strong decrease. Parentheses indicate eventual effects. 
Table modified from [40]. 
Parameter Aspirator 
rate ↑ 
Air 
humidity 
↑ 
Inlet 
temperature 
↑ 
Atomising 
air flow ↑ 
Feed 
rate ↑ 
Heat 
capacity 
of 
solvent 
↓ 
Concen-
tration 
of feed ↑ 
Dependence 
Outlet 
temperature 
↑↑ ↑ ↑↑↑ ↓ ↓↓ ↑↑↑ ↑↑ 
Particle size -  -  -  ↓↓↓ (↑) (↓) ↑↑↑ 
Humidity of 
product 
↑↑ ↑↑ ↓↓ -  ↑↑ ↓↓↓ ↓ 
yield ↑↑ (↓) (↑) -  (↓↑) ↑↑ ↑ 
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The most important process parameters for spray drying are the drying air inlet temperature, 
outlet temperature, flow rate of the drying air (aspiration rate), atomising air flow rate and 
the residence time of the droplet in the drying chamber [34]. In paper II (Chapter 7), the 
effect of varying the inlet temperature, aspiration rate, feed rate and atomising air flow rate 
were evaluated. The residence time was not included as a variable parameter since it was 
not possible to control directly. The outputs of interest were the outlet temperature, powder 
yield, residual moisture, reconstitution properties, and the size and morphology of the 
particles after rehydration. The temperature of the inlet air directly influences the airs 
ability to dry and the rate of evaporation. The aspiration rate is directly influential on the 
obtained powder yield as increased flow rates increase rotational speed and thus the 
sedimentation force of particles in the cyclone (Figure 26). However, it also increases the 
speed at which droplets move through the drying chamber, decreasing drying time and thus 
possibly increasing the residual moisture. The atomising air flow rate controls the droplet 
size with higher flow rates giving smaller droplets. Smaller droplets give shorter drying 
times and generally provide smaller powder particles, however, its effect on the size of the 
rehydrated particle was unknown [35]. The effect of the process parameters on particle 
morphology and reconstitution properties was also unknown. The architecture and 
morphology of spray dried particles are controlled by the feed composition and by the 
distribution of compounds in the particles. The latter is affected by a number of complex 
phenomena related to the composition of the feed and by the rate of evaporation from the 
droplet (i.e. the drying rate). A “slow drying rate”, in which the diffusional motion of the 
solute is fast compared to the radial velocity of the receding droplet, allows diffusional 
rearrangement of molecules during drying and often leads to the formation of solid 
particles. Conversely, when the droplet surface recedes faster than the diffusional speed of 
the solutes, the solutes will concentrate on the droplet surface leading to the formation of a 
shell [28]. Ingvarsson et al. have previously spray dried pre-formed liposomes in 
suspension and found that the spray drying process affected the morphology of the 
reconstituted liposomes and that a fast drying rate was critical to preserve the liposome 
structure after drying [41]. 
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5. Microcontainers for oral vaccine delivery 
Microcontainers are micro-fabricated polymeric cylinders in the micro size range that are 
closed at one end and open at the other end. A scanning electron microscopy (SEM) image 
of the microcontainers used for this PhD on a silicon chip is shown in Figure 27. They are 
fabricated with precisely controllable dimensions with the negative epoxy photoresist SU-
8 through a two-step photolithography process.  
 
Figure 27. SEM image of the microcontainers used in this PhD project as seen from above. The 
microcontainers are produced in 25x25 arrays on a silicon wafer. 
 
For this PhD, the concept of the microcontainers is that they can be filled with vaccine 
formulation and then sealed with a polymer lid, as illustrated in Figure 28. Many vaccine 
antigens are sensitive to the reduced pH and proteases in the stomach [1]. These can be 
protected by loading the vaccine into microcontainers and sealing them with a pH-sensitive 
lid that will remain stable in the pH range of the stomach, but will dissolve in the pH range 
of the intestine [2]. Microcontainers have previously been observed to be engulfed in the 
mucus of the rat intestine [3]. We speculated that this might help particles cross the mucosal 
barrier and may help lipid particles reach APCs before emulsification by bile salts. 
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Figure 28. Concept of microcontainers for oral vaccine delivery. A powder formulation of the 
vaccine is loaded into the microcontainer and the microcontainer is then sealed with a pH sensitive 
lid. The pH sensitive lid remains intact at low pH (stomach) but dissolves at increased pH 
(intestine), thus protecting the vaccine from the harsh conditions of the stomach and releasing it in 
the intestine. 
 
In this PhD study, a spray drying process was established to produce a model vaccine in 
powder form. The vaccine consisted of powder precursors of cubosomes with the adjuvant 
Quil-A and the protein ovalbumin as model antigen. In vitro evaluation of the particle 
morphology, size, zeta potential, particle stability in dispersion, antigen content and release 
was investigated as well as the stability of the antigen during dry storage of the powder at 
room temperature. The vaccine showed promising properties for vaccination, although the 
cubosomes needed a high energy input to disperse and had limited colloidal stability. 
Further evaluation in vivo showed that the vaccine was highly immunogenic after s.c. 
administration stimulating strong antigen specific humoral and cellular immune responses. 
However, when administered orally in powder form in a capsule, no immune response 
could be detected (Paper I, Chapter 6). It was speculated that optimisation of the spray 
drying parameters might improve the reconstitution or affect the structure of the particles 
after rehydration. A design of experiments approach was employed to evaluate the effect 
of the four spray drying parameters expected to be the most influential on the product: input 
temperature, aspiration rate, atomising air flow rate and feed rate (Paper II, Chapter 7).  
Microcontainers have previously shown promise as oral delivery system in vivo in rats, as 
described in Chapter 1. However, they have never been used in mice and have never been 
evaluated for oral delivery of a vaccine. In Paper I (Chapter 6), we established that 
cubosomes are ineffective orally when delivered in a capsule. This was speculated to be 
due to degradation of the antigen by gastric acid and enzymes combined with emulsification 
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of cubosomes by bile salts. For that reason, microcontainers with pH-sensitive lids were 
considered promising for oral delivery of cubosomes. The effect of stomach fluid and 
intestinal fluid on unprotected cubosomes was evaluated in vitro and pH sensitive lids were 
designed to allow release of cubosomes in the small intestine of mice, but not in the 
stomach. Microcontainers with pH sensitive lids were evaluated in vivo as oral delivery 
system for powder precursors of cubosomes in a prime-boost setting as oral booster 
following s.c. injected prime (Paper III, Chapter 8). 
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9. General discussion 
The current study has focused on spray drying of a cubosome-based model vaccine and 
using microcontainers to deliver them orally. In vitro characteristics and the effect of 
varying spray drying parameters on the cubosomes were investigated and microcontainers 
were applied for oral delivery of the cubosomes using a pH-sensitive lid. Cubosomes and 
microcontainers were tested in vivo evaluating the potential of the system. In this section, 
important results of the studies will be discussed. 
 
9.1. Re-dispersion and colloidal stability 
For routine clinical administration of a vaccine, it is important that the vaccine formulation 
is easy to prepare. Any vaccine distributed in powder form and administered by injection 
should be able to reconstitute fully upon addition of water with gentle inversion of the 
container. Furthermore, as was established in sections 2.3 and 3.3.2.1, particles larger than 
2-3 µm may be less efficiently taken up by intestinal M cells and APCs than smaller 
particles. For oral administration of a vaccine in powder form, it is consequently important 
that the powder can spontaneously reconstitute into dispersed particles when water is 
added.  
In contrast to the easy re-dispersion reported by Spicer et al. [1] from a similar system 
(described in section 4.6), the cubosome precursors produced in this thesis suffered from 
poor reconstitution properties and limited colloidal stability. This could be related to the 
composition of the spray drying feed, the spray drying parameters, or to the large difference 
in the solids concentration used in the feed. The ratios of dextran (stabiliser) to monoolein 
(membrane forming lipid) used here and by Spicer et al. [1] are similar, and preliminary 
experiments to Paper I showed that the exact ratio is not crucial. However, OVA and Quil-
A are both surface active molecules that might affect the surface properties of cubosomes 
and hence their colloidal stability. This is supported by the change in size and zeta potential 
of the particles observed when OVA and/or Quil-A was added (Paper I). The results of 
Paper II suggest that the only spray drying parameters that affect the powders ability to 
reconstitute are the inlet temperature and aspiration rate, with a high temperature and 
aspiration rate giving better reconstitution. These parameters also resulted in a high outlet 
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temperature and a common factor for all powders that reconstituted easily was an outlet 
temperature above 110oC (Figure 29). This could indicate that a fast drying rate helps form 
powders that reconstitute easily. It has been suggested that a homogeneous distribution of 
a steric stabiliser on cubosomes helps form colloidally stable cubosomes [2]. It is therefore 
likely that it also provides easier reconstitution of the precursor powder and it was thus 
speculated in paper II that a fast drying rate is beneficial to obtain a powder that 
reconstitutes easily. Spicer et al. used a feed solution containing 40 % solids and an outlet 
temperature of 130oC [1], whereas a solids concentration lower than 1 % was used in Paper 
II with outlet temperatures ranging from 36-132oC. The effect of increasing the solids 
concentration of the feed was not investigated in Paper II, but this tends to increase the 
outlet temperature of the process (Table 3, section 4.6) because there is less solvent to 
evaporate. 
 
Figure 29. Effect of outlet temperature during spray drying on the ease of reconstitution of 
cubosome precursor powder graded from 0 (very poor) to 3 (excellent). A linear regression line 
(solid line, r2 = 0.51) with 95 % confidence interval (dotted lines) is indicated. 
 
While the outlet temperature was observed to be important for the reconstitution properties, 
it could only explain 51 % of the variation in the measured reconstitution grades in Paper 
II (Figure 29, unpublished figure). A better explanation of the poor re-dispersibility is that 
dextran is not a good steric stabiliser of cubosomes. This was suggested by Spicer et al. [1] 
due to the lack of a hydrophobic region on dextran, resulting in little interaction between 
dextran and the lipid membrane (section 4.6). Steric stabilisation of cubosomes is generally 
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necessary to prevent the particles from flocculating so they will remain as discrete colloidal 
particles [3]. The main elements required to obtain effective stabilisation are the volume 
and density of the hydrophilic stabilisation layer and the adhesion strength of the stabiliser 
onto the cubosome surface. Non-ionic block copolymers are often used for stabilisation of 
cubosomes and often comprise poly(ethylene glycol) or poly(ethylene oxide) to generate 
the hydrophilic stabilisation layer [3]. Pluronic 127 is considered the gold standard 
stabiliser and consists of the triblock copolymer poly(ethylene oxide)-poly(propylene 
oxide)-poly(ethylene oxide), which adsorbs to the surface of cubosomes [3,4]. This 
supports that dextran, due to its lack of a hydrophobic region, is likely not a good colloidal 
stabiliser of cubosomes. Adding the much better steric stabiliser Pluronic 127 to the spray 
drying feed may therefore result in a powder that is easier to reconstitute and shows better 
colloidal stability once in dispersion. The addition of Pluronic 127 does not obviate dextran, 
however, since an agent to reduce powder cohesion is still needed. 
Flocculation of cubosomes upon reconstitution was an issue for the in vivo studies. With 
macroscopic aggregates, the dose given in each injection would be impossible to control, 
the particle size would be irreproducible and such large particles might not stimulate a 
proper immune response (sections 2.3 and 3.3.2.1). It was therefore necessary to 
reconstitute using glass beads and sonication. For consistency, this practice was also used 
for the in vitro studies in Paper I. Sonication was obviously not possible for formulation 
given orally in a capsule though. Since the in vivo results of Paper I showed a slightly 
stronger immune reaction of OVA and Quil-A in solution compared to the completely 
absent response of oral powder precursors of cubosomes with OVA and Quil-A in a 
capsule, it was speculated whether reconstitution could be the issue. Figure 30 (unpublished 
data) shows that the cubosomes powder not only did not reconstitute, but kept the gelatine 
capsule in a gelled state in unstirred buffer in vitro in contrast to the complete disintegration 
seen soon after hydration at 37oC of a capsule without cubosomes.  
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Figure 30. Oral capsules in 10 mM maleic acid buffer pH 6.6 in a volume of 200 µL at 37oC 
containing nothing (left), cubosomes with OVA and Quil-A (middle), and OVA+Quil-A (right). 
Pictures taken of a) dry capsules, b) after adding buffer c) after 10 min in buffer d) after 2 h in 
buffer and e) after letting the water evaporate. f) Close up picture of capsule with cubosomes after 
2 h in buffer. 
 
In the following in vivo study (Paper III, study 1), a control group of oral cubosomes with 
OVA and Quil-A was needed to evaluate the effect of microcontainers. This time, the 
cubosomes were dispersed prior to gavage to investigate if the lack of an immune reaction 
to the oral cubosomes seen in Paper I was a consequence of lacking reconstitution. This 
was partly confirmed by the study, although the results from dispersed oral cubosomes with 
OVA and Quil-A were highly variable and the immune stimulation was not comparable to 
that of s.c. injected cubosomes at a 10 times lower dose (Paper III, study 1). The result must 
be interpreted with caution, however, since administration of water can also increase the 
intestinal uptake of particles [5]. Solving the issue of re-dispersion is therefore important, 
but not sufficient to allow oral vaccination with cubosomes. Other factors that might affect 
the oral immune response include degradation of OVA by acid and proteinases in the GI-
tract, emulsification of cubosomes by bile salts in the intestine, the ability of the vaccine to 
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cross the mucus barrier (section 2.2) and insufficient activation of individual APCs by both 
antigen and adjuvant (sections 2.1, 2.3 and 3.3.2.3). All but the last of these matters were 
attempted solved using microcontainers with pH-sensitive lids as presented in Paper III 
(Chapter 8) and will be further discussed in section 9.3. The issue of co-delivery of antigen 
and adjuvant to APCs is discussed below. 
9.2. Co-delivery of antigen and adjuvant to APCs 
Prior to the first in vivo study, it was established that 65 % of the OVA in the cubosome 
precursor powder was present in free soluble form after reconstitution and dispersion with 
glass beads and sonication. The remaining OVA was released within 24 h (Paper I). It was 
therefore interesting if Quil-A was also released quickly such that APCs would not be 
exposed to antigen before the immunopotentiator thus possibly being unable to stimulate a 
cellular immune response (section 3.3.2.3). As Quil-A is of surfactant nature and known to 
disrupt the cubosome structure at high concentration (unpublished data), it was considered 
possible that it might be incorporated into the lipid membrane. However, it is also very 
hydrophilic and consequently might also be expected to be present in the aqueous phase.  
Measuring Quil-A release from cubosomes is not easy. Quil-A is a complex mixture of 
saponins with batch-to-batch differences (section 3.3.1.3) and low light absorption [6]. 
Bobbala et al. therefore developed a high pressure liquid chromatography with evaporative 
light scattering method to quantitate Quil-A and thereby enable measuring Quil-A release 
[6]. However, Quil-A tends to clog up HPLC columns and salts, lipids, dextran and OVA 
need to be removed for the method to work (unpublished data). Salts could be avoided by 
performing the release study in phosphate buffer without the added salts of the more 
physiological phosphate buffered saline. Since the MW of the saponins of Quil-A is in the 
range of 1500-2500 Da [7], it was anticipated that dextran, OVA (MW > 40 kDa, Paper I) 
and cubosomes could be separated from Quil-A by ultrafiltration through a 10 kDa 
membrane. However, although the concentration used was below the critical micelle 
concentration of Quil-A (section 3.3.1.3), Quil-A was retained by the filter (unpublished 
data).  
A new sensor developed in Professor Anders Kristensen’s group at DTU Nanotech was 
used by Marco Crosio and Kristian Tølbøl Sørensen to measure Quil-A release from the 
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monoolein-based particles with Quil-A from Paper I (Figure 15, unpublished data). The 
results showed that Quil-A is released almost immediately after reconstitution. It must be 
stressed that this measurement was performed without the 20 min re-dispersion step used 
for the measurement of OVA release in Paper I and for all in vivo studies. It thereby 
indicates that Quil-A has been released completely prior to injection during the in vivo 
studies. It should be noted, however, that the measurement had to be done on particles 
without OVA. As these are mainly of vesicular structure rather than cubosomes (Paper I), 
the results must be interpreted with caution.  
 
 
Figure 31. Release of Quil-A from the monoolein-based particles (vesicles) with Quil-A from Paper 
I. The measurement was performed in Milli-Q water using a photonic crystal slab sensor. Data is 
represented as mean ± standard deviation (n = 3).  
 
On the assumption that Quil-A is indeed released faster than OVA from cubosomes, it 
would thus be expected that cubosomes with OVA and Quil-A should be able to stimulate 
strong humoral and cellular responses (sections 3.3.1.3 and 3.3.2.3). This was indeed 
observed after s.c. administration in Paper I, but not after oral administration in Paper I or 
Paper III. The fast release of antigen and adjuvant is a possible reason why the cubosomes 
have little effect orally, as the great dilution in the GI-tract (section 2.2) might make it 
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unlikely for individual APCs to be exposed to both OVA, Quil-A and cubosomes if OVA 
and Quil-A are not physically linked to the cubosomes.  
9.3. Microcontainers for oral delivery of cubosomes 
Microcontainers were applied to protect the vaccine from chemical and enzymatic 
degradation in the stomach and reduce the effect of bile salts in the intestine. As discussed 
in section 2.2, the GI-tract of the mouse varies substantially from that of humans and it also 
varies between mouse strains. Relying on published human data when designing an oral 
delivery system for mice is therefore risky. Paper III investigated the pH of the mouse GI-
tract to allow rational choice of pH-sensitive polymer to form the microcontainer lids. 
Eudragit® L100-55 (EL100-55) was chosen as it dissolves at pH above 5.5, which is higher 
than the gastric pH and lower than the intestinal pH of C57Bl/6 mice (the strain used in 
these studies). The rate of dissolution of EL100-55 increases with increasing pH and at pH 
6, the lids dissolve fast (unpublished observation). This provided release kinetics suitable 
for the short transit time of microcontainers through the small intestine of the mouse. 
Dibutyl sebacate (DBS) was added as plasticiser to the EL100-55 to avoid cracking during 
drying after spray coating of the otherwise brittle lids (Paper III). DBS is hydrophobic and 
insoluble in water. The use of DBS to plasticise Eudragit® E100 has been reported to result 
in a material that is more difficult to hydrate than when using a more hydrophilic plasticiser 
[8]. DBS was therefore chosen to plasticise the microcontainer lids in order to achieve lids 
with low water permeability. 
Despite the promise of microcontainers in vitro (discussed in Paper III), in vivo results were 
disappointing. Microcontainers not only did not improve the immune response stimulated 
by cubosomes with OVA and Quil-A after oral administration, but reduced it to the level 
of the negative control without OVA. This could indicate that there is an issue with the 
release of cubosome precursors from the microcontainers or with the generation of 
dispersed particles following release. Observations in paper III indicate that cubosome 
precursors should be released rapidly from microcontainers once they reach the small 
intestine and that the release kinetics of cubosome precursors from microcontainers was 
adequately fast. Recalling the discussion of section 9.1, it is therefore plausible that 
formation or dispersion of particles might be an important factor in explaining the 
disappointing results with microcontainers. 
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Doherty et al. reported on a vaccine that was unable to prime an immune response when 
administered orally, but stimulated strong protective immune responses in the lung after 
s.c. prime followed by an oral booster [9]. The booster was known to be important for the 
immune response since a single s.c. administration was ineffective [9]. This led us to 
investigate if microcontainers with cubosomes with OVA and Quil-A could be effective 
orally as booster vaccines. However, these boosters could not stimulate a cellular response 
and the humoral responses, both systemic and mucosal, were weak and inconsistent (Paper 
III). In this study though, the oral dose was the same as the s.c. dose. This might have been 
too optimistic as oral vaccination generally requires increased doses [10]. 
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10. General conclusions  
The main goal of this thesis was to evaluate microcontainers as a system for oral vaccine 
delivery. For this purpose, a vaccine in powder form was needed and the creation of a model 
vaccine in powder form was therefore the first goal of this PhD. Powder precursors of 
cubosomes with OVA and Quil-A could be produced in a fast and up-scalable manner 
through a simple spray drying process. The method was robust with the morphology and 
size of the hydrated particles being independent of the spray drying parameters within a 
wide range of settings. The spray drying parameters can therefore be adjusted to obtain 
minimal residual moisture, high powder yield and, if relevant, a low outlet temperature.  
The secondary structure of OVA was unaffected by the spray drying process. Furthermore, 
the powder could be stored for 6 months at room temperature and heated to 86oC for 24 h 
without affecting the secondary structure of OVA. The powder formed cubosomes in the 
nano-size range after reconstitution and the cubosome structure was stable over time in 
aqueous dispersion although the particles showed limited colloidal stability. The adjuvant 
Quil-A did not affect the structure of the particles despite its surfactant properties and a 
large content of OVA could be included in the powder. However, some of it may have been 
freely present in the powder as it was freely present outside the particles after reconstitution 
and dispersion.  
Hydrated cubosomes stimulated strong humoral and cellular immune responses in mice 
after s.c. administration but not after oral administration. Microcontainers were evaluated 
as oral delivery system and appeared promising in vitro being able to encapsulate the 
cubosomes at stomach pH and rapidly release them at intestinal pH. The fast release was 
important due to a short intestinal residence time of the microcontainers in mice. 
Nevertheless, in vivo results were disappointing and indicated together with the in vitro 
characteristics of the cubosomes that a better vaccine needs to be used for delivery in the 
microcontainers. An important characteristic to improve include the ability of the vaccine 
powder to reconstitute and disperse spontaneously upon addition of water into colloidally 
stable nanoparticles. Other factors that may be important are prevention of separation of 
antigen and adjuvant from the particle and improved stability of the particle in the intestine 
after release from the microcontainers.  
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11. Future perspectives 
One of the main drawbacks of the spray dried cubosome vaccine was its poor ability to 
reconstitute and disperse into small particles. Adding a better colloidal stabiliser such as 
Pluronic 127 is an important future direction for spray dried cubosomes. Ingvarsson et al. 
found that trehalose is a good stabiliser for preformed liposomes during spray drying [1]. 
Trehalose is also reported to be a good stabiliser for proteins [2] and thus changing dextran 
with trehalose might be beneficial in later studies, especially for use with more fragile 
proteins/peptides than OVA.  
Quil-A is not suitable for human vaccines due to limited natural resources, batch-to-batch 
differences and toxicity. Replacing it with a safer and more reproducible alternative such 
as a synthetic analogue of QS-21 would be preferable. For improved immunogenicity, it 
should be considered to join QS-21 with other immunopotentiators such as MPLA. 
Cubosomes also may not be the best particle for oral delivery with microcontainers due to 
their sensitivity to bile salts and their fast release of antigen and adjuvant. Evaluation of the 
importance of physical linkage of antigen and adjuvant to the particles in an oral setting 
would be an important contribution to the future design of oral vaccines. An interesting 
alternative to cubosomes is VLPs formulated to prevent rapid release of antigen and 
adjuvant. VLPs may be composed of capsid proteins of an enteric virus and thus might be 
more stable than cubosomes in the small intestine. In addition, as VLPs are preformed 
particles, their behaviour might be more predictable in vivo than cubosomes.  
The microcontainers used in these studies were microfabricated in a cleanroom from the 
negative epoxy photoresist SU-8 using a photolithography process. This method is not 
compatible with the inexpensive large scale manufacturing generally required for 
commercial vaccines and thus must be replaced. Roll-to-roll manufacturing is currently 
being pursued in our group to address this issue. The microcontainers used in this study are 
furthermore not biodegradable. This did not seem to cause any adverse effects in the mice 
during the studies of this PhD as the microcontainers were simply defecated along with 
other indigestible particles that the mice had ingested. However, it may complicate 
licensing by regulatory authorities. It may therefore be preferable to make microcontainers 
from a biodegradable polymer that has already been used in licensed products such as 
PLGA. 
164 
11.1. Bibliography 
[1] P.T. Ingvarsson, S.T. Schmidt, D. Christensen, N.B. Larsen, W.L.J. Hinrichs, P.
Andersen, J. Rantanen, H.M. Nielsen, M. Yang, C. Foged, Designing CAF-
adjuvanted dry powder vaccines: spray drying preserves the adjuvant activity of
CAF01., J. Control. Release. 167 (2013) 256–64. doi:10.1016/j.jconrel.2013.01.031.
[2] T. Sou, E.N. Meeusen, M. de Veer, D.A. V Morton, L.M. Kaminskas, M.P.
McIntosh, New developments in dry powder pulmonary vaccine delivery, Trends
Biotechnol. 29 (2011) 191–198. doi:10.1016/j.tibtech.2010.12.009.
Copyright: Christoffer von Halling Laier
All rights reserved
Published by:
DTU Nanotech
Department of Micro- and Nanotechnology
Technical  University of Denmark
Ørsteds Plads, building 345C
DK-2800 Kgs. Lyngby
